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Clinical trials targeting hematopoietic stem cells and T cells for treatment of genetic 
disorders and cancers with chimeric antigen receptors, respectively, are finding increasing 
success using Human Immunodeficiency Virus (HIV)-derived lentiviral vectors (LVs)1-4. 
Improved safety and efficacy of current generation self-inactivating LVs, which can infect 
non-dividing cells that are often targets of clinical gene therapy, provide an attractive 
option for gene transfer of therapeutic transgenes5, 6.  Despite these advances, LV 
manufacture remains inefficient, scale-limited, and expensive7. Lengthy ex vivo cell 
transduction protocols often require large quantities of LV to achieve the desired clinical 
outcomes8, 9. Ongoing clinical studies expose the limitations of the technology and 
highlight the need for improvements in clinical LV transduction efficiency as entire LV 
production runs may dose a single patient. Attempts to improve transduction through the 
use of polycations10, spinoculation11, recombinant fibronectin fragment coatings12, or 
biological adjuvants13 have been explored previously. High throughput screening has also 
been unsuccessful in identifying transduction-enhancing reagents14. Unfortunately, the 
sheer vector requirements for high levels of gene transfer remain problematic due partially 
to large minimum working volumes of standard transduction systems such as culture plates, 
flasks, and bags.  
Moreover, the multiplicity of infection (MOI), a commonly used parameter 
representing the ratio of viral particles to target cells in a given transduction, has 
consistently proven to be unreliable to predict dosages of LV necessary for therapeutic 
benefit15, 16. As such, multiple rounds of transduction at MOI 100 is not uncommon in 
 xvii 
clinical protocols. Instead, vector concentration is more recently emerging as a 
standardized parameter for transduction17, 18. The movement toward requisite LV (v/v)% 
for effective transduction suggests diffusion limitations inherent in standard transduction 
platforms, requiring increasingly larger amounts of LV as transduction systems are scaled 
toward clinical usage19. Therefore, significant amounts of LV are wasted in these systems. 
The goal of this work was to investigate the use of microfluidics in clinical gene 
therapy to develop a novel platform for more efficient LV-mediated transduction. Several 
microfluidic devices have been developed in the Lam laboratory using different methods 
in order to achieve this goal (Chapter 3). By investigating factors such as MOI, (v/v)%, 
transduction height (diffusion distance), and transduction times in microfluidic devices 
compared to well plates requiring larger working volumes, we determined that microfluidic 
devices could be leveraged to create a more efficient transduction platform for gene therapy 
that significantly reduces the amount of virus required for efficient gene transfer (Chapter 
4). Furthermore, we demonstrate that our system offers improvements in primary human 
T cell (Chapter 5) and murine ex vivo hematopoietic stem cell (Chapter 6) transduction 
with less LV requirements and shorter transduction times.  With clinical gene therapy 
advancing rapidly into commercial application, associated advances in vector 
manufacturing and utilization will be essential to routine clinical implementation and 
globalization. Improvements in vector manufacture will not necessarily result in greater 
transduction efficiency. Extrapolating insight gained from this study to cost evaluations of 
ongoing clinical trials, we estimate that an order of magnitude reduction in vector costs per 
patient may be attainable by using microfluidics. Due to the large number of sources of 
variability in vector titration and inconsistent infectivity between various cell types, the 
 xviii 
strategy for many clinical trials to achieve therapeutic transduction has essentially been to 
apply as much vector onto cells as possible without inducing detrimental toxicity. 
Continued development of the microfluidic transduction system may enable a more 
systematic approach to gene therapy that would also significantly reduce the wastes 








CHAPTER 1: INTRODUCTION 
 
 
Through decades of research and innovation, viruses that once plagued humanity 
with sickness and disease have been transformed into tools with the potential to provide a 
permanent cure for various genetic disorders and cancers. In recent years, researchers and 
clinicians have achieved success in treating a variety of diseases using viruses that have 
been reprogrammed to transfer therapeutic genes rather than inducing pathogenesis1, 2, 20, 
21. Though the technology has finally matured from proof of principle to true clinical 
efficacy, gene therapy is still restrained to phase I/II clinical trials due to complex and 
costly manufacturing that hamper progression to phase III/IV clinical trials and 
commercialization.  
 
1.1  Motivation 
 
Genetic hematologic disorders and malignancies such as sickle cell anemia, 
hemophilia, and acute lymphoblastic leukemia currently affect millions of people 
worldwide with several hundred thousand estimated new cases occurring annually. Disease 
management thus far has been limited to allogeneic bone marrow transplantation, injection 
of recombinant clotting factors, frequent blood transfusions, drugs, surgery, or radiation. 
However, such treatments severely limit the lifestyles of patients, and may not always 
prove to be effective. Many hematologic disorders are inherited, which makes them viable 
targets for clinical gene therapy since CD34+ hematopoietic progenitor cells can be 
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harvested from the patient, genetically corrected ex vivo, and then transplanted back to 
minimize immunogenicity and provide a method for the patient to repopulate the body with 
healthy cells that produce functional proteins. Similarly, T cells genetically modified to 
express chimeric antigen receptors (CARs) have shown promise in the eradication of 
hematologic malignancies, which would normally avoid detection in the body4, 22.  
Lentiviral vectors (LVs) provide an attractive method for cell transduction, the 
process of inserting foreign deoxyribonucleic acid (DNA) into a cell with a viral vector, 
due to their ability to infect non-dividing cells with stable integration of DNA6. However, 
progress in the field has been severely hampered by low transduction efficiencies of current 
platforms despite various efforts to improve virus-cell interactions. The multiplicity of 
infection (MOI) is a commonly used parameter for viral transductions to determine the 
theoretical number of viral particles that will enter a target group of cells15. However, much 
higher MOIs, and therefore greater quantities of virus, are often used clinically to achieve 
any significant transduction efficiency depending on the cell type.   
Previous studies have shown that viral transduction is a diffusion-limited process 
governed by Brownian motion19. With currently utilized methods, due to the short half-life 
of these self-inactivating viruses, many of the viral particles will never reach the target 
cells before decaying, resulting in the observed low rates of gene transfer. These barriers 
are mildly circumvented by using high concentrations of LV, which is both cost-prohibitive 
and potentially toxic to the target cells. Thus, there is a clear need to develop a more 
efficient platform for lentiviral transduction to limit the amount of virus necessary to 
achieve therapeutic levels of transduction.   
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Microfluidic devices can be designed to have a high surface area to volume ratio 
that allows for small sample volumes to be used23. Combined with the ability to perfuse 
fluids with tight control of flow conditions, microfluidics provide a novel technical 
capability in the gene therapy field that enables cells to be exposed to high vol./vol. 
concentrations of LV without increasing the amount of virus used, thereby overcoming the 
diffusion limitations and waste associated with current methods of viral transductions.  
 
1.2  Research Objectives and Specific Aims 
 
The long term goal of this work is to develop strategies to enhance the lentiviral 
transduction efficiency for clinical gene therapy. The overall objective of this project was 
to design microfluidic devices to promote more effective transport of viral particles to 
target cells. The central hypothesis of this project was that leveraging various microfluidic 
features could significantly reduce the amount of virus necessary to achieve therapeutic 
levels of gene transfer.  This hypothesis was grounded upon the well-documented 
utilization of microfluidics for reagent miniaturization in biomedical research due to their 
high surface area to volume ratio, and was tested with these specific aims: 
 
Specific Aim 1: Design and develop various microfluidic devices for lentiviral 
transduction of non-adherent cells. The working hypothesis of this aim was that the high 
surface area to volume ratio of μFluidics would enhance lentiviral transduction efficiency 
compared to current transduction protocols conducted in well plates. Microfluidic devices 
of varying sizes and materials were designed in the Lam laboratory to develop a 
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microfluidic platform for lentiviral transduction, and are described in detail in Chapter 3. 
A GFP-encoding lentiviral vector was used to transduce non-adherent K562 and Jurkat 
cells serving as a surrogate of the hematopoietic target cells of clinical gene therapy. 
Efficiency of immobilization of cells in the devices and their removal were also 
characterized. From the work conducted toward this aim, we were able to demonstrate the 
feasibility of a microfluidic transduction platform with a small-scale device.  
 
Specific Aim 2: Determine and optimize key parameters for achieving therapeutic levels 
of gene transfer using microfluidics. The working hypothesis of this aim was that 
determining parameters that directly impact transduction in the microfluidic could lead to 
better design and utilization to further improve transduction efficiency. A systematic 
approach was used to determine how mass transfer principles interact with existing 
biological and biochemical adjuvants to affect transduction efficiency and kinetics. GFP 
expression was assessed via flow cytometry to evaluate transduction efficiency. A 
computational model of the transport of viral particles to cells in the microfluidic versus a 
cell culture well allowed for parameters such as virus concentration, cell density, and fluid 
height to be assessed in silico. Chapter 4 discusses the findings of these studies, in which 
we narrowed down the parameter space to achieve efficient transduction using 
microfluidics. Together, these parameters were optimized to develop a scaled up 
microfluidic device and transduction protocol capable of transducing upward of 106 cells, 
a relevant goal for preclinical trials.  
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Specific Aim 3: Translate the microfluidic lentiviral transduction technology to clinically 
relevant LV products and systems. The working hypothesis of this aim was that existing 
protocols for clinical transductions could be adapted for use with microfluidics. Primary 
human T cells were transduced in the microfluidics using clinical grade LV encoding for 
GFP or a high titer coagulation factor VIII (fVIII) LV. Transduction efficiency and cell 
viability were assessed by measuring GFP expression and 7AAD dead cell staining via 
flow cytometry. Vector copy number (VCN) was measured by the real time polymerase 
chain reaction (RT-PCR) to determine true virus integration and efficiency of transduction. 
The findings and results of our work with primary human T cells can be found in Chapter 
5. Microfluidic transduction efficacy was also assessed in vivo using primary murine Sca-
1+ hematopoietic stem and progenitor cells from C57BL/6J hemophilia A mice. The 
isolated cells were transduced in a standard 6-well and in the microfluidic transduction 
system with the fVIII-LV for direct comparison. Transduced cells were then transplanted 
into lethally irradiated hemophilia A donor mice. Transduction efficiency and engraftment 
were assessed by measuring fVIII plasma levels via chromogenic assay and flow 
cytometric analysis of recipient versus donor cells, respectively. Vector copy number was 
measured from cells of the blood, spleen, and bone marrow after at least 8 weeks when 
fVIII levels typically stabilized. These results are discussed in Chapter 6. 
 
1.3  Significance of Results 
 
This work presents significant contributions to the fields of gene therapy, 
hematology, cancer immunotherapy, and cell manufacturing. It is clear that transduction 
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efficiency is the limiting factor to clinical translation of gene therapy applications. 
Hematopoietic stem cells (HSCs) are one of the most promising and frequently utilized 
cellular targets for ex vivo lentiviral vector-based gene therapy applications, which include 
the correction of several inherited diseases8. The reason for their attractiveness is now well 
defined. HSCs have the ability to self-renew, as well as differentiate into all lineages of the 
hematopoietic system. Engineered T cells are also proving to be remarkably efficacious 
anti-cancer agents24. However, despite some early phase 1/2 clinical trial successes, the 
field remains severely hampered by inefficient LV manufacturing and target cell 
transduction. The microfluidic transduction platform and the concepts developed from this 
work address these limitations by offering greater utilization efficiency of this severely 
limited resource simply by adapting existing protocols to a different system. While the 
implications for the potential of this work to impact clinical gene therapy are tremendous, 
microfluidics also have the potential for use as a more accurate tool to assess viral titer. 
The high transduction rates yielded from the microfluidics were often higher than expected 
from the amount of LV added to the system, indicating that the titer may be lower than 
reported. This was not surprising, considering that the current process to calculate viral 
titer is also diffusion limited, as discussed elsewhere previously16. The scalability of this 
platform also provides a powerful clinical tool that can allow for optimization of viral 
dosages through small-scale transductions. Overall, this investigation of using microfluidic 
devices designed specifically for lentiviral transduction clearly demonstrates the versatility 
of this platform, which offers virus and time savings, and has various modes of use 
depending on constraints.   
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CHAPTER 2: BACKGROUND AND LITERATURE REVIEW 
 
2.1  Gene Therapy 
 
2.1.1 Basic Principles of Gene Therapy 
 
Gene therapy is the process of modifying a patient’s genetics for therapeutic 
benefit. This effect can be achieved in a variety of methods including transduction using 
viral vectors, introduction of exogenous nucleic acids through non-viral vectors, and 
genome editing techniques that can remove or insert gene segments at desired locations. 
Genetic modification is a broad term that can be achieved by, but is not limited to the 
addition or replacement of a gene, knockdown of a pathogenic gene, or complete correction 
of a mutated gene. Vectors can be delivered directly to specific targets in vivo or utilized 
ex vivo whereby cells are collected, modified outside of the body, and transplanted back 
into the patient. The scope of this work focuses specifically on lentiviral vectors and their 
applications in ex vivo hematopoietic stem cell transplantation and cancer immunotherapy.  
 
2.1.2 Key Events in Gene Therapy History 
 
The concept of gene therapy was originally conceived even before Watson and 
Crick had discovered the double helix structure of DNA25. Several decades of research 
drawing from the fields of genetics, molecular biology, and virology have resulted in a 
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maturing sub-field of clinical medicine that aims to provide solutions to “incurable” 
diseases. In this section, we will describe some major milestones in gene therapy history 
that propelled the field forward or resulted in major setbacks. Extensive gene therapy 
history reviews including the basis and discovery of genetics and the transfer thereof can 
be found elsewhere, but are beyond the scope of this work26-28. The viral vectors discussed 
in this section will primarily focus on the impact these vectors made on the field. Section 
2.1.3 will instead summarize more details and tradeoffs of different viral vectors.  
As early as 1980, researchers were introducing cloned genes into mammalian cells. 
Notably, Martin Cline piloted a controversial human gene therapy trial in β-Thalassemia 
patients without permission from the UCLA institutional review board29. Although no 
clinical benefit was achieved, the patients also did not experience any negative effects. This 
trial was conducted following two other animal studies by Cline where murine bone 
marrow cells were transfected with genes to produce dihydrofolate reductase and another 
where murine bone marrow cells had again been transfected with a herpes simplex 
thymidine kinase gene to confer methotrexate resistance30, 31. All studies utilized a calcium 
phosphate transfection method where a calcium phosphate-DNA precipitate is formed to 
facilitate binding of DNA to the cell surface, which then induces endocytosis for DNA 
delivery32.  However, severe criticism of these animal studies imply that advancing to 
human subjects may have even been unwarranted29. While the backlash of this incident 
was severe and left a negative mark on Martin Cline’s career, it made some positive 
contributions to the progression of gene therapy by quelling fears at the time of safety 
concerns and sending a clear message to investigators to adhere to the established rules and 
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regulations in addition. All future human gene therapy trials would henceforth be required 
to receive approval by the NIH Recombinant DNA Advisory Committee (RAC). 
Around that same time, retrovirus research had advanced well enough that many 
groups began developing retroviral vectors for in vitro correction of human cells. Three 
different research groups are credited for independently developing retroviral vectors 
nearly concurrently: Shimotohno and Temin as well as Wei et al. in 1981 and Tabin et al. 
in 198233-35. The growth of retroviral vector usage created a notable shift from chemical 
transfection techniques to viral vectors for gene therapy. Not only were the retroviral 
vectors more efficient than chemical transfection, but they demonstrated efficacy in human 
and other mammalian cells. In vitro treatment of human disease was demonstrated in 1983 
by Miller et al., in which they corrected cells obtained from humans deficient in 
hypoxanthine phosphoribosyltransferase (HPRT) with a retrovirus expressing human 
HPRT36. By 1986, Kantoff et al. showed that retroviral vectors could be used to correct 
adenosine deaminase (ADA) deficiency severe combined immunodeficiency disease 
(SCID)37.  
In 1988, the RAC approved the first clinical protocol for gene transfer into humans. 
The goal of the study was not for gene therapy, but instead for human gene marking in an 
attempt to track tumor-infiltrating lymphocytes (TILs) in patients with metastatic 
melanoma for treatment optimization38. By modifying the TILs to confer resistance to 
neomycin, the in vivo distribution and survival of the cells could be determined. This study 
successfully demonstrated that genetically modified cells derived from retroviral vectors 
could be safely administered to humans with implications for the use of lymphocytes in 
future gene therapy applications. Following the first RAC approval for human gene 
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transfer, the FDA approved the first human gene therapy clinical trial in 1990. Michael 
Blaese directed the effort to use retroviral vectors to treat ADA-SCID in two children by 
transducing their T cells to produce the ADA enzyme that was deficient in their condition20. 
The patients were still given polyethylene glycol (PEG)-ADA, so the extent of the 
therapy’s effectiveness was unclear. However, the dosage of PEG-ADA was able to be 
reduced, indicating that the therapy was viable. Overall, the study further supported the 
claim that retroviral vectors could offer safe gene therapy treatments for patients with 
ADA-SCID.  
 Several clinical trials followed into the next decade. However, the first gene 
therapy-related death caused major setbacks to the field. On September 17, 1999, Jesse 
Gelsinger experienced lethal complications directly related to the adenoviral vector 
administered for the treatment of a partial ornithine transcarbamylase deficiency (OTCD)39, 
40. This occurred a mere 98 hours after receiving the vector, resulting in systemic 
inflammation and multi-organ failure. Investigations of possible mechanisms of action 
point to innate immune responses from certain components of the vector capsid. 
Adenoviral vectors are typically administered in vivo, bearing greater risk to immune 
responses. Soon after that tragic incident, another major setback for the gene therapy field 
occurred. A SCID-X1 gene therapy trial led by a group of researchers in Paris initially 
reported the first “cure” for a disease using a retroviral vector in April 200041. X-linked 
SCID-X1 syndrome is a fatal disease that is caused by a deficiency in the γ-c chain receptor, 
which prevents developing lymphocytes from maturing into functional T cells and natural-
killer cells. By delivering a functional γ-c chain receptor gene to hematopoietic stem cells, 
the treated patients were able to develop functional immune systems. However, two of the 
 11
three patients eventually developed disorders that bared similarities to leukemia. The 
complications are believed to have developed from insertional mutagenesis caused by 
vector integration close to or in the LMO2 oncogene, leading to uncontrollable replication 
that likely resulted from single transduced cells in which the oncogene was activated.  
These two events triggered researchers and clinicians worldwide to re-evaluate the risks of 
gene therapy, stalling its progression for several years.  
Lentiviral vectors soon found increased usage and emerged as the safer alternative 
to many of the other viral vectors42. They also offered key advantages that were unavailable 
with other vectors such as the ability to stably integrate into both dividing and non-dividing 
cells6. Due to its derivation from the human immunodeficiency virus Type 1 (HIV-1), there 
was a major focus on biosafety. By the third generation, LVs were stripped of six of the 
nine genes that encode for virulent components, leaving them as self-inactivating and 
replication incompetent without altering their ability to transfer genetic material5, 43.  
In 2012, the European Union recommended Glybera (alipogene tiparvovec), the 
first commercial gene therapy product in the Western world, for approval. Glybera is an 
adeno-associated viral (AAV) vector used to treat lipoprotein lipase (LPL) deficiency, 
which is an orphan disease that causes inflammation of the pancreas due to the buildup of 
abnormally large particles of fat in the blood44. However, estimates of the cost for this 
therapy are as high as $1,000,000 for the average adult, which would require several rounds 
of intramuscular injections of the vector. As such, the model for payment of such an 
expensive drug is still undetermined due to the novelty of pricing a curative therapy45. 
Thus, there is a clear need to push for commercialization of other gene therapy products 
that remain in Phase I/II testing.  
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2.1.3 Viral Vectors Used in Clinical Gene Therapy 
As discussed in the previous section, LVs are not the only option for gene transfer 
in a clinical setting. However, among the various vectors, LVs are the best option for 
targeting hematopoietic stem cells and T cells, the major targets of ex vivo gene therapy. 
They are the only vector that can integrate into both dividing and non-dividing quiescent 
cells, have a relatively large packaging capacity, and can integrate their genome into target 
cells for a potential lifelong cure.  
 



























4.5 kb 70 – 90 nm 5 kb 
Lentivirus Integrating Dividing and 
Non-dividing 
cells 
8 kb 80 – 130 nm 3 – 9 kb 
Retrovirus Integrating Dividing Cells 
Only 
8 kb 80 – 130 nm 3 – 9 kb 
 
2.2  Production of Lentiviral Vectors 
Lentiviral vector stocks are generated from transient transfection of producer cell 
lines using the calcium phosphate method32, 46. Typically, human embryonic kidney (HEK) 
293T cells are used due to their high rates of transfection and protein production. The third 
generation design of lentiviral vectors utilizes four plasmids to encode for fully active 
lentiviral particles that lack virulent elements and the ability to form functional 
recombinants43. One plasmid contains the therapeutic transgene of interest while the 
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remaining three plasmids are required for the packaging of LVs. In particular, these are 
often pMDL, pRev, and pVSVG for vesicular stomatitis virus glycoprotein (VSV-G)-
pseudotyped LVs. The pMDL plasmid encodes for Gag-Pol precursor proteins that form 
structural proteins, integrase, and reverse transcriptase that are common to all retro- and 
lentiviruses. The pRev plasmid provides the Rev gene, which is necessary for the 
production of LV particles from the producer cell lines. Finally, the fourth plasmid encodes 
the envelope protein. pVSVG is a popular choice due to the broad tropism of the VSV-G 
envelope, enabling transduction of a variety of cell types47. Other envelope proteins may 
be used in favor of VSV-G for specific targeting of different cell types48. 
After transient transfection, the media is exchanged to allow for transiently 
transfected cells to produce lentiviral particles. The supernatant, which should contain viral 
particles within 24 hours, is then collected and stored, and fresh media is added back to the 
cells. This process may be repeated, but is limited due to the cytotoxicity related to VSV-
G, gag, and pol expression in producer cell lines47, 49-51. When all viral supernatant has been 
collected from a given production run, it is then filtered to remove cell debris, though the 
titer will still be low. To obtain higher titer LV stocks, the filtered viral supernatant is 
concentrated by ultracentrifugation at speeds as high as 70,000g for 2 hours at 20°C. 
Further ultracentrifugation through a sucrose cushion or chromatography-based 
purification can be performed to remove residual contaminants from LV production that 
may contribute to vector toxicity46. However, this step can also lead to a reduction in titer.  
Large scale production conforming to current good manufacturing practices 
(CGMP) has been characterized7. All materials and reagents must also conform to CGMP 
conditions, including the lentiviral plasmids. The process must be able to produce 
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consistent batches of LV, and the resulting product must meet an expensive panel of 
specifications including sterility and pH requirements, as well as testing negative for 
mycoplasma and replication competent lentivirus. Additional processing is also required 
to remove residual additives such as benzonase and DNase, which are used to degrade 
contaminating DNA from the transient transfections. Despite the large scale production, 
final volumes ranging from 56-574 µL were achieved, with titers ranging from 5.2-3.0 x 
108 TU/mL after 7-12 weeks of virus production per production run. A pediatric clinical 
trial utilized 180mL batches ranging from 2.1-7.6 x 108 TU/mL titers for each patient, 
highlighting the severe bottleneck to commercialization due to the limitations in vector 
production combined with high vector requirements from low transduction efficiency1. 
 
2.3  Existing Additives Used to Enhance Transduction Efficiency 
Many commercially available products have been developed to enhance 
transduction efficiency. These compounds are typically added during transduction to 
facilitate binding of virus to cells, though their mechanisms of action differ. 
2.3.1 Polycations 
 
Hexadimethrine bromide, more commonly known as polybrene, is a commonly 
used reagent in gene therapy to enhance transduction efficiency by reducing charge 
shielding between the negatively charged surfaces of cells and viral envelope by providing 
a positive charge as a bridge (Figure 2.1)10, 52 . Protamine sulfate is another popular 
cationic polymer that is considered to work similarly to polybrene, but with reduced 
toxicity53. However, both of these additives are shown to induce mild toxicity and anti-
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proliferative effects at high concentrations54. Therefore, a balance between transduction 
enhancement and toxicity should be considered before use. A dosage of 8 µg/mL is 





Figure 2.1: Proposed mechanism of polycation gene transfer enhancement. Polycations 
provide a positive charge to reduce the charge shielding between the negatively charged 
surfaces of cells and viral particles. 
 
 
2.3.2 Recombinant Fibronectin Fragments 
 
 
RetroNectin is a recombinant fibronectin fragment that is believed to enhance 
transduction efficiency using retroviral and lentiviral vectors by bringing cells and viral 
particles in closer contact for binding (Figure 2.2)12. The RGDS peptide sequence of 
fibronectin binds to the variable lymphocyte antigen (VLA)-5 integrin (α5β1) while the CS-
1 peptide sequence binds the VLA-4 integrin (α4β1). RetroNectin also contains a heparin-
binding domain, which contains positively charged amino sidechains for binding of the 
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negatively charged surfaces of the viral particles. Thus, RetroNectin can also be used to 
immobilize cells when adsorbed to surfaces. In an optimized protocol for retroviral 
transduction in RetroNectin-coated bags, Dodo et al. suggest that RetroNectin is better 
adsorbed onto materials such as polystyrene, cyclo-olefin, polyethylene, and Teflon 
compared to other materials such as ethylene vinyl acetate and polyolefin55. A major 
limitation of RetroNectin usage is its steep cost at $1,442 per 2.5mg of CGMP-grade 
product. The suggested surface concentration is 4-20µg/cm2, which would be enough to 




Figure 2.2: Hypothesized mechanism for RetroNectin enhancement of gene transfer. Cells 
can bind to the fibronectin RGDS cell-binding domain and the CS-1 site via VLA-5 and 
VLA-4 surface integrins, respectively. Retrovirus and lentivirus binds to the heparin-
binding domain. Binding of cells and virus bring them in close proximity to enhance 
transduction efficiency. Image taken from Takara RetroNectin product manual.  
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2.3.3 Biological Adjuvants 
 
Rapamycin is an immunosuppressive compound that is normally used to prevent 
organ transplant rejection. Recent studies have investigated the use of rapamycin for 
enhancing transduction efficiency of lentiviral vectors in hematopoietic stem cells. It was 
found to increase LV cytoplasmic entry through enhancement of endocytic events 
following LV binding (Figure 2.3)56. As such, rapamycin is the only transduction 
enhancing compound that acts by modulating cellular functions rather than enhancing 
nonspecific binding to the cell surface. More characterization of the effects of rapamycin 
are required, but FDA approval is still required since use in clinical transduction protocols 




Figure 2.3: Rapamycin enhances post-binding viral entry into cells, which has the 






2.4  State of the Art Transduction Methods and Their Limitations 
 
In addition to using additives for enhancement of transduction efficiency, 
alternative methods in the way transductions are actually performed have been developed 
in an effort to further enhance transduction efficiency. These include spinoculation, 
magnetofection, and flow-through transductions. 
2.4.1 Spinoculation/Spinfection 
Named for its mechanism of action, spinoculation or spinfection works by 
centrifuging virus and cells together so that the virus is deposited onto cells (Figure 2.4). 
Spin speeds on the order of 103 x g are typical to achieve enhancement11. However, 
ultracentrifugation is typically used to concentrate LV stocks, which requires 
centrifugation speeds as high as 25,000 RPM (104-105 x g)57. At such relatively low spin 
speeds, it is surprising that spinoculation works as proposed. Guo et al. showed that 
centrifugation at the elevated speeds enhance viral binding, entry, postentry DNA 
synthesis, and nuclear migration by modulating actin and cofilin activity rather than purely 
by virus sedimentation58. In addition to requiring cells to be exposed to high centrifugal 
forces, spinoculation protocols also require cells to be kept at room temperature for several 
hours outside of a CO2 environment while spinoculation occurred. As such, it may not be 










 In a related method, Le Doux et al. described a process in which cationic and 
anionic polymers were added at an equal-weight ratio were added to retroviral stocks to 
form high molecular weight precipitates consisting of retrovirus and polymer complexes, 
which could then be simply centrifuged at low speeds to deposit virus onto cells59. This 
method was shown to enhance gene transfer by 10-20 fold compared to the original 
retroviral stock formulation without the charged polymers.   
2.4.2 Magnetofection – Magnetic Nanoparticle-based Transduction 
Coupling LVs with magnetic nanoparticles have demonstrated some efficacy in 
enhancing transduction efficiency. Similar to spinoculation, this method relies on 
physically manipulating virus for deposition onto cells (Figure 2.5). Magnetofection was 
originally demonstrated for use with nucleic acids or adenoviral vectors, but ViroMag and 
LentiMag are both commercially available products that are marketed toward forming 
magnetic nanoparticle complexes with lentivirus or retrovirus to surpass diffusion 
limitations and enhance transduction efficiency60. Shamir et al. have demonstrated the use 




Figure 2.5: Schematic of magnetofection mechanism. Magnetic nanoparticles form 
complexes with virus, which are then brought into closer proximity with target cells using 
magnetic force to increase virus-cell binding. 
 
 
2.4.3 Flow-through Transductions 
Instead of relying on centrifugation or magnetic forces to bring virus to cells, Chuck 
and Palsson described a method that relied on fluid flow to direct retroviral particles to 
cells (Figure 2.6)19, 62, 63. The cells were immobilized on a porous mesh so that virus could 
come into contact with the cells while virus-containing media was passed through. Despite 
being conceptualized in the mid-1990s, this method has not gained widespread use in 
clinical gene therapy as initially proposed.  
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Figure 2.6: Schematic of flow-through transductions. Flow-through transductions require 
cells to be immobilized on a porous mesh while virus-containing media is flowed directly 
through the mesh so that viral particles are targeted directly at cells.  
 
2.5  Problems with Standard Systems 
2.5.1 Standard Systems Have Large Working Volumes 
One of the major issues with standard systems is the large working volume, which 
drastically increases the LV requirements when LV v/v% is used as the standardized metric 
to determine vector dosage16. As such, the difference between a microfluidic and a 
comparable well plate could be as much as an order of magnitude greater LV usage (Figure 
2.7). For a given surface area, fluid height/diffusion length also increases proportionally 





Figure 2.7: Microfluidics enable minimization of LV usage to maintain specific LV v/v% 
concentrations. Comparable systems requiring larger working volumes would significantly 
increase LV requirements to maintain the same concentration. 
 
2.5.2 Diffusion Limitations 
Related to the issue of large working volumes are diffusion limitations. Static 
transductions rely on Brownian motion for the transport of viral particles to cells19. 
However, retroviral and lentiviral vectors have been shown to have short half-lives of 6-10 
hours64. From an estimation of mean square displacement of a retroviral particle with an 8-
hour half-life, Chuck et al. estimated that the viral particle would only be able to be 
displaced 480-610µm by Brownian motion within one half-life19. Therefore, most of the 
virus is wasted in standard diffusion limited systems, making microfluidics a suitable 
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platform to natively enhance transduction efficiency while maintaining compatibility with 
the additive compounds and state of the art technologies aimed at increasing transduction 
(Figure 2.8).  
 
Figure 2.8: Schematic of issues with diffusion-limited systems. Microfluidics are a 
potential solution to overcoming these diffusion limitations for enhanced transduction. 
 
2.6  Titration of Lentiviral Vectors 
One of the major issues leading to wasteful usage of vector arises from the fact that 
determination of the number of infectious particles are in a given LV preparation stock 
solution is non-trivial and subject to extreme variability with differences on the scale of 
orders of magnitude65. Here we discuss some of the different methods currently used to 
calculate titer, and describe some issues associated with these methods. 
2.6.1 Physical Titer 
Enzyme-linked immunosorbent assays (ELISAs) can be used to measure the p24 
antigen, which is a component of the envelope protein for VSV-G pesudotyped LVs46. 
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Quantification of titer using this method gives the amount of vector particles in nanograms, 
though it does not necessarily correlate with functional vector particles66. As such, the 
physical titer may often be an overestimate of the actual amount of infectious particles due 
to the detection of unincorporated p2467. Using this method, serial dilutions of vector are 
tested using ELISA kits for the p24 antigen, and an average titer can be calculated. 
2.6.2 Biological Titer 
By including a reporter gene such as GFP in the transfer plasmid, a biological titer 
can be calculated by transducing cells with serial dilutions of the vector stock and assessing 
transduction using flow cytometry. From this method, the number of transducing units 
(TU) can be calculated per microliter (TU/µL) can be backwards-calculated from the 
percentage of transduced cells, the number of cells plated at the time of transduction, and 
the volume of vector added to each condition46, 68. However, vector integration does not 
perfectly correlate with protein expression due to position-effect variegation69. Since the 
transgene integrates at semi-random locations, the gene may sometimes remain inactive 
despite integrating into the genome due to abnormal positioning with the heterochromatin. 
This method may also be combined with RT-PCR to quantify how many copies of the 
vector transgene have integrated into the target cells, though the issues of diffusion 
limitation may still cause the titers to be underestimated using this method15, 16. Together, 
these various methods are used to correlate the amount of input vector with gene expression 
of transduced cells (Figure 2.9)66. The serial dilutions must cover a wide enough range 
such that the upper limit results in a saturation of vector, leading to a plateau in 
transduction. By calculating the slope of the linear portion of the curve, the titer of 
infectious transducing units can be estimated for future experiments. 
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Figure 2.9: Examples of titration curves for lentivirus titer determination. Calculations are 
made by calculating the slopes of the linear portions of the curves. Image taken from [66]. 
 
2.7  Multiplicity of Infection is Unsuitable to Predict Transduction 
In the fields of gene therapy and virology, the multiplicity of infection (MOI) is a 
parameter that is commonly used to define a particular dosage of viral vector. It is given 
by the ratio of viral particles to the number of target cells exposed to virus. Having a 1:1 
virus to cell ratio, with the MOI being equal to 1, does not guarantee that every cell will be 
infected by a single virus. Viral entry is a statistical process in which some cells will remain 
uninfected while others will be infected by multiple viruses. The population of infected 
cells is therefore best described by a Poisson distribution.  
 
The Poisson distribution is a discrete probability distribution that gives the 
probability of an event occurring over time or space given a known average instance of 
occurrence (Equation 1).  
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In the context of viral infections, if there is a single viral particle and a single cell 
within a confined space, the cell should theoretically be infected once given sufficient time. 
This corresponds to a MOI of 1. Therefore, λ is equivalent to the MOI, which represents 1 
viral infection per cell. In practical terms, transductions usually target anywhere from 
thousands to millions of cells rather than just a single cell. As the number of cells increase 
over a given area, the number of viral particles added to the system must also increase to 
maintain the 1:1 virus:cell ratio for MOI 1. Due to the increased number of targets for the 
viral particles, there is now a heterogeneous population of cells that have varying numbers 
of viral infections. The Poisson distribution can therefore approximate the distribution of 
probabilities for a given cell being infected by k viral particles with a specified MOI, λ.  
With this information, the percentages of cells containing at least 1 vector copy can be 
approximated by calculating the probability that a cell remains uninfected and subtracting 
from unity (Equation 2).  
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Defining the multiplicity of infection with these assumptions provides a theoretical 
framework for determining how many cells can ideally be transduced for a given MOI. 
This defines the upper limit of transduction. In practical usage, there are definite 
limitations. The viral particles are not stable, and have a half-life on the order of hours 
when incubated with cells at 37°C64, 70. Furthermore, diffusion limitations prolong the time 
taken for viral particles to reach cells, making it so that many viral particles will never have 
a chance to reach cells before decaying. Biological differences such as expression levels of 
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the receptors to the virus envelope will also determine binding of cells to virus for 
infection71. This can drastically create discrepancies in observed transduction versus 
theoretical achievable transduction based on MOI. For this reason, MOI has been criticized 
as an unreliable parameter16, 72. Since determination of viral titer is also diffusion limited, 
different theories regarding viral infectivity and titer have been generated. Some groups 
have posited that there are mixtures of infectious and non-productive viral particles while 
others have argued that it may not actually be an issue, and diffusion limitations play a 
larger role19, 73.  
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CHAPTER 3: DEVELOPMENT OF A MICROFLUIDIC PLATFORM 
FOR LENTIVIRAL TRANSDUCTION 
 
3.1  Introduction 
The creation of an entirely new interdisciplinary field began with the realization 
that semiconductor technology, traditionally used for the production of microchips, could 
be used for analysis and manipulation of fluids at the microscale. Early usage of 
microfluidic technology began with chemical analysis, providing benefits such as 
miniaturization and low reagent consumption with high sensitivity. Since then, 
microfluidic utility has expanded to a multitude of applications including molecular 
analysis, diagnostics, cell assays, physiologically recapitulated in vitro systems, cell 
sorting, and various other fields of biomedical research.  
3.2  Fabrication Techniques Used for Lentiviral Transduction Microfluidics 
Microfluidic devices can be produced using a variety of methods depending on 
material choice or the tolerances required, which are determined largely by the constraints 
of the application. Devices that rely heavily on precise fluid physics often rely on advanced 
fabrication techniques that require cleanroom facilities and expensive equipment. 
Alternative relatively inexpensive fabrication techniques exist, which can greatly reduce 
the complexity of production while retaining key advantages conferred by microfluidics. 
However, reproducibility and resolution are lost using these techniques compared to more 
traditional techniques. The following sections will cover different fabrication methods used 
to produce microfluidic devices for lentiviral transduction. 
 29
3.2.1 Photolithography 
Of all methods used to produce the microfluidic lentiviral transduction devices for 
this study, photolithographic methods enable the highest resolution and reproducibility, but 
require the most time and specialized equipment to generate. A master mold, usually 
consisting of a silicon or glass wafer patterned with a photosensitive epoxy called 
photoresist, must be made in a cleanroom. SU-8 is a popular choice of photoresist for soft 
lithography due to its ease of use and durability. Typically, a computer aided design (CAD) 
drawing of the microfluidic devices is submitted to a photomask company for production. 
The photomask is a soda-lime glass or quartz substrate coated with a layer of chrome, in 
which laser etching or electron-beam lithography is used to produce the desired patterns. 
These methods of patterning can be used to produce extremely high resolution photomasks, 
down to the sub-micron scale depending on the method used and the limitations of the 
tools. The master molds that are used to produce the actual microfluidic devices are made 
by patterning photoresist onto a glass or silicon wafer by exposing ultraviolet (UV) light 
through the photomask, which either crosslinks the photoresist or makes it soluble to 
special chemicals known as developer solution depending on the type of photoresist used. 
The microfluidic devices themselves are typically made from an optically 
transparent silicone elastomer known as polydimethylsiloxane (PDMS). A crosslinking 
agent is typically mixed with the PDMS at a 1:10 ratio (crosslinker:PDMS), which hardens 
the PDMS as the crosslinker evaporates. Increasing the temperature accelerates the 
reaction. Curing PDMS on the silicon master molds results in the transfer of patterns to the 
PDMS. In the case of microfluidic channels, the master mold consists of raised features of 
the channel patterns, which become trenches in the PDMS when peeled from the mold. 
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After punching inlet and outlets and covalently bonding to another PDMS or glass surface 
using a plasma bonder, the trenches are sealed, resulting in a fully enclosed microchannel. 
This method can be repeated hundreds of times to consistently produce microfluidic 
devices as long as the integrity of the master mold is maintained. A schematic of the process 
is shown below in Figure 3.174 and an example of the SU-8 mold used for microfluidic 




Figure 3.1: Schematic of fabrication process for microfluidic devices using 
photolithography and soft lithography. (a) SU-8 photoresist is spun onto a silicon wafer. 
(b) UV light is exposed to the photoresist through a photomask or transparency to transfer 
the pattern. (c) Uncrosslinked photoresist is removed using photoresist developer. (d) 
PDMS is poured and cured on the mold. (e) The PDMS is cut and detached from the mold. 
(f) Inlet and outlet holes are punched, and the channel is covalently bonded to a flat sheet 




Figure 3.2: Silicon mold of scaled up transduction device made using photolithography. 
Scale bar = 10 mm. 
 
3.2.2 Computer Numerical Controlled Micro-milling of Master Molds 
For larger devices that do not require high resolution features, computer numerical 
controlled (CNC) micro-milling can be used to produce metal master molds75. Depending 
on the channel design, producing a master mold with this method may actually be 
preferable since producing a thick uniform layer of photoresist is not always feasible. The 
turnaround time to produce a master mold from a CAD drawing is also much faster than 
possible with photolithography using this method. However, this technique is limited to a 
minimum height of approximately 200µm and minimum feature gaps of 381µm (0.015”). 
In this study, a CNC mill (HAAS OM 1) (Figure 3.3a) was used to remove material from 
the top surface of an aluminum block using a 1/16” end-mill to a depth of ~200µm. The 
spindle speed used was between 20,000 and 25,000 RPM at a feed rate of 5”/min. The 
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scaled up transduction device was large enough that there were no issues achieving the 
desired channel widths. After a few de-burring steps and smoothing, the aluminum master 
mold can be used similarly to a silicon master mold (Figure 3.3b). However, the channel 
walls will not be as smooth, though this was not critical for the transduction devices.  
 
 
Figure 3.3: Examples of CNC mill and resulting microfluidic mold. A) HAAS OM 1 CNC 
mill used to produce aluminum molds for microfluidics. B) Resulting aluminm mold of 
scaled up transduction microfluidic. Scale bar = 10mm. 
 
3.2.3 Microfluidic Xurography 
For rapid prototyping of microfluidic designs, microfluidic xurography can be used 
to produce devices without requiring master molds entirely76. Xurography refers to the 
process of creating patterns with the use of a razor blade. This can easily be achieved with 
an inexpensive craft cutter, which is normally used for cutting patterns into paper, vinyl, 
or other similar sheets. Instead, microfluidic devices can be made by cutting patterns into 
thin films or double-sided adhesives. The lentiviral transduction microfluidics used in this 
study were produced by cutting patterns into a silicone double-sided adhesive (3M, St. 
A B 
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Paul, MN, USA) with a Silhouette craft cutter (Silhouette America, Inc., Lindon, UT, 
USA). The patterned adhesive was then applied to either a polystyrene petri dish or a flat 
sheet of PDMS, which served as the base. A thicker block of PDMS with pre-punched inlet 
and outlet ports was then adhered to the top surface of the silicone adhesive to fully seal 
the channel. The thickness of the adhesive layer determines the channel height. The entire 
process is summarized in Figure 3.4. Due to minor perturbations as the razor blade is 
dragged across the surface, the cut silicone adhesive becomes frayed, resulting in a 
microfluidic channel with smooth top and bottom surfaces from the PDMS/polystyrene, 
but rough sidewalls. Decreasing the cutting speed helps to reduce the roughness, but the 
sidewalls will never be as smooth and well-defined compared to microfluidics made from 
a silicon master mold. However, this method was sufficient to produce rapid prototypes for 
the microfluidic lentiviral transduction device. Previous studies have determined that the 
resolution for this technique are dependent on the cutter, but also by factors such as blade 




Figure 3.4: Schematic of simplified microfluidic fabrication using xurography. A craft 
cutter is used to cut channel patterns in a double-sided silicone adhesive. The adhesive is 
transferred to a thin piece of PDMS or petri dish and then sealed off with a thicker piece 
of PDMS with inlet and outlet ports punched in. 
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3.2.4 Hot Embossing of Thermoplastics 
Though most microfluidic devices are made from PDMS, some applications require 
the microfluidics to be made from different materials. Thermoplastics are a popular 
alternative for mass production of disposable microfluidics, though up front tooling costs 
make it undesirable for prototyping of different devices designs. To that end, we developed 
a simplified prototyping method to produce polystyrene microfluidics from PDMS molds 
(Figure 3.5)78. Using PDMS molds enables micro-scale patterns beyond the resolution of 
other fabrication techniques to be transferred directly to the polystyrene79. Other embossing 
methods have higher production throughput, but require specialized tools such as a heated 




Figure 3.5: Schematic of perfusable PS device fabrication for cell culture. (1) Cut out a 
PDMS mold from patterned photoresist of the desired channel geometries and treat with 
HMDS. (2) Pour PDMS (5:1 ratio PDMS:crosslinker) onto the HMDS treated mold and 
cure to produce a PDMS die with raised features of the channel. (3) Emboss the channel 
into a PS slide using the PDMS die in a convection oven. (4) Allow the PS to cool before 
removing pressure. Edge beads will form around the perimeter. (5) Trim the edge beads 
off and drill inlet and outlet ports. (6) Silanize the top surface. (7) Thermally bond a thin 
sheet of PS to the embossed PS using approximately 10 kPa pressure for 5 min. (8) Create 
a PDMS port with tapered holes and plasma treat the device and PDMS to covalently bond. 
 
From an SU-8 master mold, the peeled PDMS can be treated with 
hexamethyldisilizane (HMDS) for use as a PDMS master mold, which can then be used to 
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cast additional PDMS to obtain a negative of the original pattern. The negative pattern 
serves as a PDMS die, which can be used to transfer the pattern directly to a thermoplastic 
such as polystyrene when distributed heat and pressure are applied. The embossed 
polystyrene channel can then be coupled with a thin sheet of bare polystyrene to thermally 
bond the two pieces together, sealing the channel. Following silanization treatment of the 
embossed polystyrene using (3-Aminopropyl)triethoxysilane (Sigma-Aldrich, St. Louis, 
MO, USA), a bare block of PDMS with pre-punched inlet and outlet ports can be plasma 
bonded for use as an adapter for inlet and outlet ports. Using a PDMS die for pattern 
transfer results in smooth surfaces, though deformation of the PDMS can occur if the 
embossing pressure is too high, resulting in altered channel dimensions.  
However, under optimized conditions, uniform channel dimensions can be 
reproduced without distorting the cross-sectional area as shown by 3D material confocal 
scanning (Figure 3.6a) and confocal microscopy z-stack of a polystyrene channel filled 
with fluorescently tagged bovine serum albumin (BSA) (Figure 3.6b). The devices were 
also robust enough to withstand high enough shear stress for HUVEC flow culture. No 
device leakage was observed for shear stress below 300 dyn/cm2, with critical failure 




Figure 3.6: PS device characterization. (a) 3D laser material confocal scan of embossed 
channel profile. (b) Reconstructed z-stack of bonded channel filled with fluorescent BSA. 
(c) Plot of the percentage of devices that were able to be perfused continuously for at 
least 100 hours without leakage for various shear stresses. n = 3. Scale bars = 200 µm. 
 
Finally, we determined that polystyrene microfluidics could be used to culture 
human umbilical vein endothelial cells (HUVECs) under flow to achieve a confluent 
monolayer encompassing all surfaces and adopting a phenotype that aligned with the flow, 
which was the first demonstration of perfusion-based HUVEC culture in a polystyrene 
microfluidic of size scale less than 100µm (Figure 3.7a and b).  
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Figure 3.7: Endothelialization of PS device. (a) Phase contrast images of zoomed out 
branch region. (b) Confocal fluorescence image of endothelial cells in the smallest branch 
(width < 100 µm) with orthographic views showing flow alignment and confluency along 
all channel walls. Red = cell membrane and green = cell nuclei. Black scale bars = 200 µm 
and white scale bars = 50 µm. 
 
Although a cleanroom is still required to produce the initial master mold, all 
additional steps can be completed using common equipment found in most laboratories. 
This method serves as a simple way to prototype thermoplastic microfluidic designs. Once 
a suitable design is selected, more advanced methods such as injection molding can be used 
to produce higher quality microfluidics with greater throughput.  
3.3  Material Selection 
Microfluidic devices can be made from a variety of materials with the earliest types 
being made from silicon and glass81. With the development of soft lithography, PDMS 
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offered a robust alternative that simplified production and became a mainstay for 
microfluidic device material selection82. As the applications of microfluidics expanded, 
different material properties were required, prompting the exploration of alternative 
material choices. Thermoplastics such as polystyrene and polymethylmethacrylate were 
thus used due to their higher stiffness and decreased permeability83. Finally, demand for 
more physiologically compatible long-term culture of cells in microfluidics called for 
hydrogel microfluidics84, 85. For the lentiviral transduction microfluidics, ease of 
fabrication and protein adsorption were determined to be the most important properties 
affecting material selection. As such, all microfluidic devices designed for lentiviral 
transduction were made from either PDMS or polystyrene.  
3.3.1 Polydimethylsiloxane (PDMS) 
From the conception of soft lithography, polydimethylsiloxane (PDMS) has been 
greatly favored by bioengineers due to its prototyping cost-effectiveness, ease of use, and 
high level of reproducibility from master molds, enabling a large range of microfluidic 
applications for biological research including cell analysis and cell culture86. In 
determining different design considerations for a microfluidic lentiviral transduction 
platform, devices made entirely from PDMS were the path to greatest consistency and 
production throughput. Furthermore, the elasticity of PDMS allows for loading of cells and 
connection of tubing to a syringe pump for media exchange since the PDMS can deform 
to produce an interference fit. Gas permeability is another important characteristic of 
PDMS, since it allows for crucial gas exchange to occur within the microchannels and 
provides a means of removing any air bubbles that form within the device.  
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Most importantly, PDMS is generally accepted to be biocompatible87. PDMS-based 
microfluidics have been used for in vitro recapitulation of the microvasculature due to the 
small size scale and flow-based cell culture made possible by microfluidics. These studies 
have shown that cells can be cultured within microfluidics for several days with no negative 
effects on cell viability or alterations to cell physiology (Figure 3.8)88. 
 
 
Figure 3.8: Example of HUVEC culture in PDMS microfluidics. Red stain is a membrane 
dye. Blue stain is a nuclear dye. Scale bar = 50µm.  
 
 Moreover, PDMS typically has poor cell adhesion properties, requiring 
functionalization with adhesive proteins89. Taken together, these properties demonstrated 
potential for PDMS to be used in a microfluidic lentiviral transduction platform since cells 
have been shown to remain viable in microfluidic culture for the duration of typical 
transduction protocols and PDMS exhibits tunable adhesion for efficient cell removal or 
immobilization for flow-based transductions. 
3.3.2 Polystyrene 
Polystyrene was another suitable material choice for the lentiviral transduction 
microfluidic. As the most characterized and commonly used substrate material for cell 
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culture, it was conceivably beneficial for microfluidic cell culture to be conducted in 
polystyrene-based microsystems23. In addition, there have been a few reports of potential 
drawbacks of PDMS-based devices, including uptake of small hydrophobic molecules 
from the media, leaching of uncrosslinked oligomers into the culture media, and 
hydrophobic recovery of the channel surfaces, which were of concern since cells would 
have to be transduced within the microfluidic for at least several hours to as much as several 
days90. Finally, RetroNectin, a recombinant fibronectin fragment that contains binding 
domains for both non-adherent cells and lentivirus for increased virus-cell contact, has been 
suggested to be optimally adsorbed onto polystyrene, cyclo-olefin, polyethylene, or 
Teflon55. 
 From our experience with endothelialized polystyrene-based microfluidics, we 
initially explored hot embossed hybrid PDMS-polystyrene microfluidic devices for our 
microfluidic lentiviral transduction platform. In addition to a RetroNectin coating, our 
device contained embossed micro-divots to provide greater surface area for increased cell 
adhesion during flow-based transductions. By applying the same silanization technique 
directly to the embossed polystyrene channel91, we were able to produce a hybrid PDMS-
polystyrene microfluidic that could efficiently immobilize cells on the bottom polystyrene 
surface while retaining gas permeability for long term cell culture. The modified 




Figure 3.9: Schematic of hybrid polystyrene-PDMS device, which can be used for 
lentiviral cell transduction. Steps 1-4 are similar to those shown in Figure 3.5. Briefly: (1) 
Cut PDMS from silicon mold and HMDS treat. (2) Pour PDMS (5:1 PDMS:crosslinker) in 
HMDS-treated PDMS mold to produce a PDMS die. (3) Emboss. (4) Allow to cool and 
remove die. Additional trimming is not necessary. Silanize the top surface. (5) Punch inlet 
and outlet ports in a flat slab of PDMS and align with the embossed channels (6) The 
completed device will enable non-adherent cells to be immobilized in the embossed divots 
within the emboss channels, allowing for an immobilized cell layer to come into 
homogeneous contact with a lentiviral media layer. 
 
Although we were able to achieve enhanced transduction based on estimates from 
image analysis (Figure 3.10a and b), we determined that the hot embossing method was 
unsuitable for the production throughput required in order to properly characterize the 
system as a lentiviral transduction platform. Furthermore, scaling up toward clinically 
relevant cell numbers would not be trivial. We investigated if traditional PDMS-based 
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microfluidics could be sufficient by assessing three key parameters: 1) Long-term culture 




Figure 3.10: K562 cells transduced in the hybrid polystyrene-PDMS device. (a) Phase 
contrast image of K562 cells immobilized in the divots. (b) Fluorescence image of cells 
expressing GFP after 24 hours of perfusion of lentiviral media followed by a 96 hour 
incubation period. Cells can be seen expressing GFP at various levels. Scale bar = 100 µm. 
 
3.4  PDMS-based Device Characterization 
3.4.1 RetroNectin Immobilization Efficiency 
Although RetroNectin is optimally adsorbed onto plastic surfaces such as 
polystyrene and cyclo-olefin55, we sought to determine if RetroNectin adsorption to PDMS 
would also be sufficient since many other adhesive proteins such as fibronectin, collagen, 
and fibrinogen have been shown to be effectively adsorbed onto PDMS surfaces for cell 
culture88, 89. Using a surface concentration of 1.05 µg/cm2, we were able to conclude that 
having RetroNectin did indeed have an impact on cell immobilization, as demonstrated by 
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cell retention after mild perfusion at 1 µL/min (  = 2.4 s-1) (Figure 3.11a and b). This 
surface concentration is nearly fourfold less than the recommended minimum surface 
concentration from the Takara product specifications. To avoid having to use trypsin or 
high flow rates to remove cells from the device, we used the minimum empirical surface 
concentration that would immobilize most of the cells for the lower range of flow rates 
examined for flow-based transductions.  
 
 
Figure 3.11: Assessment of RetroNectin coating on PDMS. a) RetroNectin-coated 
microfluidics or b) negative control bare microfluidic following mild perfusion. Scale bars 
= 100µm.  
 
Quantitation of the RetroNectin immobilization efficiency was characterized by 
loading cells inside PDMS microfluidics compared to polystyrene 6-wells, with and 
without RetroNectin coatings. Cells were incubated for 2 hours to allow cells to settle and 
adhere to the bottom surfaces. The microfluidics were perfused with PBS for one hour at a 
flow rate of 1mL/hr. Effluent containing non-immobilized cells were collected and counted 
following perfusion. The 6-well plates were similarly flushed with PBS, and aspirated to 
collect non-immobilized cells. The number of cells recovered from flushing were 
compared to the initial cell count loaded into the microfluidics and 6-wells to obtain a 
a b 
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percentage of cells recovered from flushing (Figure 3.12). No significant differences were 
detected between cell recovery from 6-wells and microfluidics, though RetroNectin 
coatings significantly decreased cell recovery after flushing (2-way ANOVA, p<0.001). 
 
 
Figure 3.12: Cell immobilization quantification with and without RetroNectin in 
polystyrene microfluidics compared to PDMS microfluidics. 
 
3.4.2 Cell Recovery Efficiency 
 
For shorter transduction times, the RetroNectin coating may not be necessary since 
transductions can be performed under static conditions without the need for media 
exchange by perfusion. Under these conditions, it is preferable to minimize cell adhesion 
to the microfluidic surfaces. To determine if there was any significant non-specific 
adhesion that reduced cell recovery from the devices, we incubated bare microfluidics and 
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6-wells with 1, 2, and 4 million cells for 5 hours and compared them to cell count controls 
to obtain a recovery percentage (Figure 3.13).  
 
 
Figure 3.13: Cell recovery efficiency of microfluidics versus 6-wells for various cell 
numbers.  
 
No significant differences in cell recovery were observed between the microfluidic 
and 6-well, indicating that use of PDMS-based microfluidics for lentiviral transduction 
does not result in decreased yield compared to standard systems. 
 
3.4.3 Long-term Microfluidic Cell Culture 
 
Typical transduction protocols call for exposing cells to virus overnight, and often 
require multiple rounds of transduction, which could result in up to 48 hours of exposure 
to vector92. To ensure that a PDMS-based microfluidic lentiviral transduction system 
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would be suitable for long term immobilization and cell culture without adverse effects, 
we transduced and cultured cells under flow in RetroNectin-coated devices. A mixture of 
virus and cells were loaded into devices. Cells were incubated for 2 hours to allow most of 
the cells to settle to the bottom surface of the channel and adhere to the RetroNectin. A 
syringe pump loaded with LV-containing media was then connected to the microfluidic 
and flowed at 0.577 µL/min for 6 hours. Afterward, LV-free growth media was perfused 
through the microfluidics for 72 hours and epifluorescence imaging was used to assess 
transduction. This proof-of-concept test demonstrated that cells could be transduced 
uniformly throughout the channel (Figure 3.14a and b) and continued to expand in culture, 
indicating that cell viability and proliferation were unaffected. Furthermore, issues of 
sterility did not arise, as all cell loading and manipulation was performed in a sterile cell 
culture hood. The channels provided a sealed environment that isolated cells from non-
sterile environments. Devices made from silicone adhesive xurography were sterilized and 
assembled under sterile conditions. The microfluidics were also placed inside sterile petri 
dishes for an added barrier against contamination. Potential issues in sterility could be 




Figure 3.14: Epifluorescence images of cells transduced and cultured in microfluidics for 
at least 3 days. a) Upstream region of the device and b) downstream region of the device, 
demonstrating heterogeneity. Scale bars = 100µm.  
 
3.4.4 Characterization of Static Microfluidic Cell Culture Viability  
Under static cell culture conditions in the microfluidic, nutrient depletion over time 
is a major concern due to the reduced volumes. To that end, we utilized ethidium 
homodimer-1 viability staining to assess cell viability from recovered cells cultured in the 
microfluidic for 5 hours. Since dead cells are not easily distinguishable from cell debris 
and other particulates that are normally gated out, quantification from flow cytometry may 
have been underestimated, but was otherwise low. Normalized percentages of ethidium 
homodimer-1 staining are shown below, with actual percentages ranging from 0.2-0.5% 
(Figure 3.15a). Cell counts were also taken immediately after removal from the 
microfluidics and 6-wells. After 72 hours of continued cell culture, cells were counted 
again to determine if cell proliferation had been affected (Figure 3.15b). Both microfluidic 





Figure 3.15: Cell viability characterization in static culture. (a) Ethidium Homodimer-1 
viability staining quantified by flow cytometry. **p<0.01 two-tailed t-test. n=4. (b) Fold 
change in cell counts after 72-hour expansion.  
 
3.5  Device Scale-up Toward Clinically Relevant Cell Numbers 
 
The original test device consisted of a series of four parallel channels, each with 
surface area equivalent to a 96-well (0.32 cm2), shown below next to the scaled up device 







Figure 3.16: Dye-loaded small and large scale microfluidic devices. The large scale device 
has the same surface area as a 6-well  (9.5 cm2) while the small scale microfluidic has the 
same surface area as a 96-well (0.32 cm2). Scale bar = 1cm.  
 
While the small scale devices had the advantage of high production throughput and 
ease of height variation, the cell throughput for transduction analysis was limiting due to 
the low cell capacity. Transductions in small scale devices were limited to approximately 
70,000 cells. Thus, we scaled up our device size to accommodate cell numbers on the order 
of 106 cells. Since it was important to compare transduction to standard cell culture 
systems, we designed the microfluidic to have the same surface area as a 6-well plate (9.5 
cm2) so that the only difference between the two systems was the diffusion height. The 
channel widths were constrained by between an upper and lower limit. Narrow channels 
would need to be longer in length, significantly increasing fluidic resistance, which would 
have impeded cell loading. Conversely, shorter wide channels would have been prone to 
collapsing due to extremely high aspect ratio, which would have required supports that 
would reduce cell recovery. Furthermore, air pockets can easily form in large channels that 
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would make uniform loading difficult. As such, we designed channels with a ~1:50 
height:width aspect ratio and used thick pieces of PDMS to prevent channel collapse. 
Different channel designs tested are shown below in Figure 3.17. 
 
Figure 3.17: Examples of different channel designs tested. All designs utilize the same 
surface area (9.5 cm2) to match a 6-well. Narrow channels require longer lengths that 
increase fluidic resistance. Wide channels are prone to collapse and heterogeneous cell 
loading and removal. A 1:50 aspect ratio was sufficient to achieve efficient and 
homogeneous cell loading. 
 
However, this marginally decreased production throughput as a single channel 
encompassed nearly the entirety of a 4-inch silicon wafer. A wide range of heights at the 
larger scale was also infeasible due to issues with uniformity over large surface areas for 




Finally, we assessed the scalability of transduction in a PDMS-based microfluidic. 
For constant MOI, transduction time, LV v/v% concentration, height, and cell surface 
density, we performed simultaneous transductions in small scale and large scale devices. 
All other factors such as LV volume, surface area, and number of cells transduced were 
scaled up by a factor of 4.8. We determined that as long as the diffusion height remained 
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constant, all other factors could be directly scaled up to achieve the same amount of 




Figure 3.18: Scaling up microfluidics by a factor of 4.8 (number of cells, total volume, 
surface area, and LV particles) while maintaining constant LV (v/v)%, MOI, channel 
height, and transduction time results in nearly identical percentages of transduced cells (n 
= 4). Data represent mean + s.d. of technical replicates from one experiment. 
 
 
Continued scale up toward clinically relevant numbers will require alternative 
fabrication methods since photolithography is typically limited to 4-5 inch silicon wafers. 
Larger wafer sizes are available, but would be extremely cost-prohibitive. CNC micro-
milling could produce a 200µm high mold with surface area of approximately 250 cm2 
(Figure 3.19). Such a device would be able to transduce 108 cells under static conditions. 
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Microfluidic xurography could be another option to produce a clinical scale device, though 
the shorter channel heights would require flow-based transductions or extremely high titer 
LV. The device could readily be fabricated using existing 245mm bioassay dishes. 
 
 
Figure 3.19: Example mock-up of a clinical scale device mold capable of transducing 108 








CHAPTER 4: DETERMINING CRITICAL PARAMETERS 
AFFECTING TRANSDUCTION EFFICIENCY 
4.1  Introduction 
In Chapter 3, we discussed different microfluidic fabrication methods and design 
considerations for developing our microfluidic lentiviral transduction platform. We 
decided to pursue PDMS-based devices due to their reliable fabrication, low batch-to-batch 
variability, and comparatively high throughput relative to polystyrene-based hot embossed 
microfluidics. Our preliminary data showed that cells could be easily removed from 
PDMS-based devices with high efficiency, but that PDMS is also able to be sufficiently 
coated with RetroNectin for immobilization of non-adherent cell types in perfusion-based 
transductions.  
In this chapter, we sought to narrow down the parameter space of microfluidic 
transduction to determine which factors were most critical to enhancing transduction 
efficiency. From preliminary experiments, we showed that simply using the same amount 
of LV in a microfluidic versus a comparable well plate could improve transduction. By 
virtue of shifting from a diffusion-limited system to a microfluidic, there are inherently 
major differences presented. Although parameters such as surface area, cell number, 
transduction time, and amount of LV used are identical, other parameters such as 
fluid/diffusion height and total volume are significantly reduced by 1-2 orders of 
magnitude, which increases the LV v/v% as a direct result. As such, diffusion limitations 
are overcome, and transduction is enhanced.  
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4.2  Materials and Methods 
4.2.1 Microfluidic Device Fabrication 
All devices were designed to have equivalent surface area to a comparable 
polystyrene well plate. Small scale devices had matching surface area with individual wells 
of a 96-well plate (0.32 cm2) while all large scale devices had matching surface area with 
individual wells of a 6-well plate (9.5 cm2). 
Small scale devices with volumes ranging from 1-15µL and 92µL large scale 
devices were made using traditional soft lithography as described in Section 3.2.1. The 
small scale devices were used for all experiments requiring microfluidic devices of varying 
heights and volumes. Of all small scale devices, only the 3µL device was used for the half-
life assessment experiments. The 92µL devices were used for all other cell line experiments 
except for the transduction kinetics experiments. Briefly, a thick layer of SU-8 2025, 2050, 
2100, or 2150 photoresist (MicroChem, Westborough, MA, USA) was spincoated onto a 
silicon wafer to achieve a uniform layer. For a 30 second spin at 3000RPM, the thickness 
of the photoresist should be equal to the last 3 digits of the specific formulation of SU-8.  
The spin speeds were adjusted to achieve the desired heights of the channel. The photoresist 
was baked at 95°C according to manufacturer guidelines to drive out the solvent. The 
device pattern was then crosslinked into the photoresist by exposing the coated wafer to 
365nm wavelength UV light through a photomask containing the desired patterns. 
Uncrosslinked photoresist was removed by treatment with SU-8 developer. The completed 
molds were treated with hexamethyldisilizane (Sigma-Aldrich, St. Louis, MO, USA) 
overnight by evaporation onto the surface before casting PDMS (Sylgard 184) (Dow 
Corning, Midland, MI, USA).  
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Microfluidic devices for assessment of transduction kinetics were made using 
double-sided silicone adhesive transfer tape (3M, St. Paul, MN, USA). Channel patterns 
were drawn using AutoCAD software (Autodesk, San Rafael, CA, USA). The channels 
were then cut from the double-sided silicone adhesive using a Silhouette craft cutter 
(Silhouette America, Inc., Lindon, UT, USA). The double-sided silicone adhesive 
containing the channel pattern was then applied to a 150mm polystyrene petri dish, 
followed by a flat slab of PDMS with inlet and outlet ports pre-punched to seal the channel. 
The resulting device was 48µL in volume with a height of approximately 50µm. 
4.2.2 RetroNectin Coating of PDMS Microfluidics 
Devices were coated with 10 µg RetroNectin (Takara Bio Inc., Kusatsu, Shiga, Japan) (1.05 
µg/cm2) the day before transduction. 6-well plates were also coated with the same amount 
for static controls. 2% BSA in PBS was incubated in the devices and 6-wells for 30 minutes 
at room temperature to block non-specific binding immediately before transduction. The 
blocking solution was then flushed out with PBS and aspirated from the devices and 6-
wells prior to use. 
4.2.3 Jurkat and K562 Culture and Transduction 
K562 and Jurkat cells (ATCC) were cultured in RPMI 1640 media supplemented 
with 10% fetal bovine serum (FBS), L-Glutamine, 25 mM HEPES, and 1% Pen/Strep. 
GFP-LV was supplied by Expression Therapeutics, LLC (Tucker, GA, USA) and was 
prepared by commercial manufacturing organizations for clinical development of a CD34+ 
fVIII-LV gene therapy product candidate. The GFP-LV utilized the EF-1 Alpha promoter, 
which provides constitutive expression of the target transgene for a broad range of cell 
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types. For all transductions, the amount of LV used between microfluidics and comparable 
well plates were identical unless otherwise noted. All cell line transductions used 8µg/mL 
polybrene. To maintain equal amounts of LV and cells, stock mixtures of cells and LV for 
specified MOIs were prepared. Microfluidic devices were then loaded with the appropriate 
volume to fill the channels. Well plate comparisons were loaded with the same volume and 
diluted to the indicated volumes in the 96-wells and to 1mL total volume in the 6-wells. 
After the specified transduction times, cells were washed with PBS, collected into 15mL 
conical tubes, and centrifuged at 200 x g. The supernatant was then aspirated to remove 
unbound residual vector, and cells were re-suspended in fresh growth media for continued 
culture.  
4.2.4 Spinoculation Comparison 
Using a similar spinoculation protocol to O’Doherty et al., we adjusted the 
incubation times so that 2,000,000 cells could all be exposed to the same amount of LV for 
the same total amount of time across all conditions. Cells were centrifuged at 1200 x g at 
room temperature in a 6-well plate for 2 hours followed by a 3-hour incubation at 37°C. 
Total volume had to be increased to 2mL so that the entire well plate surface would remain 
wetted. Cells were then processed as normal to stop the transduction as described in Section 
4.2.3. 
4.2.5 Secondary Transductions for Residual LV Qualification 
Residual LV from transduction kinetics was assessed for MOI 0.43 conditions at 
0.5, 1, 2, 6, 12, and 24 hours. At each time point, cells were removed from the microfluidics 
and 6-wells. Instead of discarding the supernatant after centrifugation, the supernatant was 
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collected and added to 1,000,000 naïve Jurkats and re-suspended with fresh media with 
8µg/mL polybrene to a total volume of 2mL. All secondary transductions were conducted 
in a 6-well for 6 hours. In doing so, all conditions would have equal cell numbers, total 
volume, fluid height, and transduction time. The only difference was the amount of LV in 
each well, which should be proportional to the amount of residual LV from the primary 
transductions.   
4.2.6 Consecutive Transductions for LV Replenishment in Microfluidics 
PDMS 92µL microfluidics were coated with RetroNectin as described in Section 
4.2.2 to immobilize cells. A single dose of vector mixed with cells at MOI 1.2, equating to 
30% LV v/v% concentration, was initially pipetted into the devices for 4 hours for the 
consecutive transductions. After four hours, a second dose of cell-free LV at the same MOI 
was loaded into the devices to replace the spent vector. A 1.5mL tube with a hole drilled 
in the cap was placed at the device outlet to collect any non-adherent or weakly adherent 
cells. Static control transductions were carried out as described in Section 4.2.3 and also 
utilized the same surface concentration of RetroNectin. 
4.2.7 Lentivirus Half-life Temperature Sensitivity Assessment 
In order to assess LV half-life in the microfluidic, aliquots of LV were stored at 
4°C, a temperature at which LV half-life has been shown to be on the order of several 
days70, 93. As temperature increases, the LV half-life rapidly decreases to the order of 
several hours at 37°C. LV samples were removed and incubated at room temperature and 
37°C for 0, 5, 12, or 24 hours prior to transduction. After the indicated pre-incubation 
period, 70,000 cells were transduced in 3µL small scale microfluidics and 96-wells for 5 
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hours. Cells were then processed as described in Section 4.2.3 and assessed for GFP 
expression as in Section 4.2.7  
4.2.8 Transduction Efficiency Assessment 
Cells were maintained in culture following removal from the devices and wells for 
at least 72 hours before assessing GFP expression to allow time for stable gene expression. 
Transduction was quantified with a BD C6 Accuri flow cytometer. Cells were gated based 
on non-transduced controls. An example of flow cytometry histograms of non-transduced, 
well-transduced, and microfluidic-transduced cells are shown below in Figure 4.1. 
 
 
Figure 4.1: Example flow cytometry histograms of control, 6-wells, and microfluidics. 
 
4.2.9 COMSOL Modeling 
We adapted the built-in biosensor model in COMSOL as a simplified framework 
for transduction in our microfluidic system compared to a 6-well. The model utilized the 
governing diffusion equation for the transport of a dilute species (LV) and a surface 
reaction (LV binding to cells). The diffusion coefficient for LV transport in media was 
estimated from the Stokes-Einstein equation (Equation 3).  




										 3  
Where kB is the Boltzmann constant, T is the absolute temperature, η is the dynamic 
viscosity, and r is the radius of the particles in motion. The values for the input variables 
are given below in Table 4.1. Due to the similar size of retroviruses and lentiviruses, the 
diffusion coefficient used was within the range of other reported values for retroviral 
vectors16, 19, 94. 
 
Table 4.1: Values used to estimate diffusion coefficient of LV 
 
Variable Definition Value 
kB Boltzmann Constant 1.380648527 x 10-23 kg·m2·s-2·K-1 
T Absolute Temperature in Incubator 310 K 
η Dynamic Viscosity 6.913 kg·m-1·s-1 
r Particle Radius 5.0 x 10-10 m 
Together: D = 6.57 x 10-8 cm2·s-1 
 
The following differential equation (Equation 4) is solved by the COMSOL model to 
describe the transport of the LV particles, P: 
∙ 0										 4  
Where D is the coefficient calculated from Equation 3 and cP is the LV concentration for 
static transductions.  The adsorption and desorption of LV particles at the bottom surface 
of the microfluidic and 6-wells where the cells settle to results in a net flux that is described 
by the Equation 5, where the net flux at the boundary, NP is: 
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Where rads is the rate of adsorption defined by an adsorption rate, kads, and rdes is a rate of 
desorption defined by the desorption rate, kdes.  
The microfluidic was simulated as a 2D axisymmetric model of the 6-well with 
50µm height. Due to rotational symmetry of the geometry and conditions about an axis, 
running the simulation this way significantly simplified the model and reduced 
computation times. 3D modeling of the microfluidic produced identical results given the 
same inputs since all parameters were matched except for the geometry (Figure 4.2). 
Essentially, the 2D axisymmetric simulation performed calculations on a 2D rectangle and 
used symmetry to treat the microfluidic as an extremely flat disk that was 50µm in height. 
This was contrary to the 3D model, which modeled the microfluidic as a long rectangular 
channel with the same surface area and height. The model was then divided into millions 
of individual 3D elements in which the governing differential equations were applied to 
each element to simulate the input conditions. The difference between the last two points 
was less than 2%, but computational time was reduced by several orders of magnitude.  
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Figure 4.2: Comparison of 2D axisymmetric vs. 3D models of the microfluidic. For 
identical input parameters, the largest difference between the two simulations was less than 
2%. 
 
Sensitivity analysis of kads, kdes, and D for the microfluidics and 6-well 
demonstrated that adsorption rate was the determining factor for the percentage of viral 
particles bound to the cell-laden surface (Figure 4.3). The desorption constant, which is 
independent of the initial vector concentration, was not sensitive to order of magnitude 
changes. These results support other reports of virus binding as the rate-limiting step to 
transduction94. Finally, increasing the diffusion coefficient, D, did not serve to improve 
transduction in the microfluidic, but increased transduction in the 6-well, highlighting the 





















































Figure 4.3: Sensitivity analysis of COMSOL model parameters. The sensitivity of viral 
particles bound to cells with respect to order of magnitude changes in kads, kdes, and D were 
plotted. 
 
A parametric study was conducted to determine the best kads and kdes values to fit the data 
from the transduction kinetics experiment. We adjusted the values of kads and kdes to 
match previously reported values of the dissociation constant for VSV-G-LV with its 
receptor, the low-density lipoprotein receptor (LDL-R)71. The error between simulated 
and experimental results is plotted for each condition in Figure 4.4. Error was initially 
extremely high for the microfluidics, but decreased exponentially for increasing time 
while the 6-well error remained relatively steady. This highlights the need for an 
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additional parameter to model the rate-limiting steps of viral entry, which is not taken 
into account for this model.  Final values of the simulation parameters are displayed  
 
 
Figure 4.4: Error between simulated and experimental results for each time point, averaged 
between different LV amounts used.   
 
 
Table 4.2: COMSOL parameters used in model 
 
Variable Definition Value 
kads Adsorption rate constant 6 x 10-9 m/s 
kdes Desorption rate constant 6 x 10-1 mol·m-2·s-1 
D Diffusion Coefficient 6.57 x 10-12 m2·s-1 
d_sites Density of biding sites 
(n_cells/surface area) 
1.0514 x 109 mol·m-2 
radius 6-well/Effective Microfluidic Radius 0.0174 m 
n_cells Number of cells 1 x 106 
height Fluid height 1.052 x 10-3 m (6-well) 









































4.3  Results and Discussion 
4.3.1 The Influence of Diffusion Height on Transduction Efficiency 
One of the first parameters investigated was the fluid height in which transduction 
occurred. Using microfluidic devices of varying heights and comparable 96-wells with 
increasing total volumes to achieve the specified fluid heights, all transductions were 
conducted with 1µL of GFP-LV for 4 hours and 70,000 cells, resulting in a MOI of 1.27. 
As a result of varying fluid heights with constant surface area, the total volumes increased 
proportionally with fluid height. Therefore, for constant LV amount, the LV v/v% 
concentration is inversely proportional to fluid height and total volume. For every 1µL 
volume increase, the fluid height increases by 31.1µm. As expected from basic particle 
diffusion calculations, transduction is shown to be inversely proportional to fluid 
height/total volume (Figure 4.5). However, a plateau was observed for transductions in 
which the fluid heights were between 30-90µm, indicating that LV transport was no longer 
diffusion-limited as associated increases in LV concentration did not further increase 
transduction. This highlights that microfluidics enabled transductions to operate in a range 
where MOI was relevant and unencumbered by diffusion limitations. In the absence of 
diffusion limitations, estimations for vector integration based on MOI may be derived from 
a Poisson distribution. Noting that some cells will be infected multiple times while others 
remain uninfected, the Poisson distribution describes the MOI-dependent probability of 
interaction between the vector and cells. Thus, decreasing the height below 90µm did not 





Figure 4.5: Decreasing diffusion height increases transduction until saturation or toxicity 
occurs. Transductions using the same amount of LV and cells (constant MOI) for various 
volumes/fluid heights made possible only in a microfluidic system. A plateau is observed 
at heights <100μm, indicating a shift away from diffusion limitations (n = 2 8.6µL 
µFluidics, n = 3 15µL µFluidics, n = 4 for all other conditions) Data represent mean + s.d. 
of technical replicates from one experiment. Transduction time = 4 hours. 
 
4.3.2 Concentration-dependence of Transduction Efficiency 
Since the LV v/v% concentration is another factor that can change transduction 
efficiency, we investigated the effect of keeping LV v/v% concentration while varying the 
fluid height. The transduction time was kept constant at 4 hours, and 70,000 cells were 
transduced per condition. To maintain constant LV v/v% concentration with increasing 
fluid height, the amount of LV in each condition had to increase proportionally. MOI 
ranged from 0.127 to 25.4. Due to the 200-fold increase in amounts of LV between the 
lowest and highest fluid heights, the amount of transduced cells generally increased with 
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increasing LV as expected. In the case of the 96-well transductions where LV was in 
excess, a plateau was reached, demonstrating the diffusion limitations of standard systems 
(Figure 4.6). Increasing the amount of vector only marginally increased the percentage of 
transduced cells in the 96-well conditions because the added vector was still unable to reach 
the cells due to diffusion limitations for the given transduction time.  
 
 
Figure 4.6: Transduction of microfluidics and 96-wells of varying volumes at constant 
10% LV v/v% concentration demonstrates that large increases in MOI does not 




 Assuming a Poisson distribution for the probability of a cell being infected with 
one or more LV particles, we defined a utilization efficiency to compare the theoretical LV 
usage required to obtain the percentage of transduced cells observed versus the amount of 
LV actually used. Equation 6 provides the average percentage of cells that will 
probabilistically be infected by at least one viral particle for a given MOI, m. This 
percentage is calculated by determining the probability that a cell will not be infected and 
subtracting from unity. 
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Thus, the percentage of cells infected with at least 1 viral particle, or the total percentage 
of positive transgene-expressing cells, can be plotted against the MOI to estimate 
transduction for a given MOI (Figure 4.7). However, this does not factor in transduction 
time and only accounts for the amount of vector that is able to reach the cells for the given 
transduction time. As such, the results shown in Figure 4.6 highlight the discrepancy 
between MOI and actual transduction achieved. Despite using MOI 25.4, only 56.4% of 
cells were transduced, which indicates that only ~3% of the total LV reached the cells.  
 
 
Figure 4.7: Theoretical percentage of transduction for given MOI from Poisson 
distribution of infectivity. 
 
The utilization efficiency can therefore be calculated by taking the ratio of the theoretical 































distribution of virus integration with the number of viral particles actually loaded into the 
system (Equation 7).  
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Alternatively, calculating the utilization efficiency in which the numerator is directly 
calculated from the percentage of transduced cells assuming one single virus integration 
for each transduced cell provides a slight underestimate, but still reveals high utilization 
efficiency for the shortest microfluidic heights. 
Comparing fluid height with this utilization efficiency instead of the percentage of 
transduced cells reveals that microfluidics with the smallest fluid heights are actually the 
most efficient at utilizing the given amount of LV while the 96-wells all utilized less than 
10% of the available LV (Figure 4.8). Utilization efficiencies greater than 100% observed 
in the microfluidic transductions indicate that titer may be underestimated, which have 
been shown to be a result of titration being conducted in diffusion-limited systems15, 16. As 





Figure 4.8: Comparison of utilization efficiencies for constant LV (v/v)% at various 
transduction volumes. Minimizing volumes more efficiently utilizes available LV. (n = 2, 
96-well conditions, n = 3, 2µL µFluidics, n = 4 All other microfluidics). Data represent 
mean + s.d. of technical replicates from one experiment. Transduction time = 4 hours. 
4.3.3 The Effect of Cell Surface Density on Transduction Efficiency 
We used the same amount of LV and changed the number of cells plated to 
determine if the cell surface density had an effect on transduction for 92µL microfluidics 
compared to 6-wells. As the number of cells loaded into the microfluidics and 6-wells 
increased, the MOI proportionally decreased. The range of MOI changed from 0.25 to 2 
for 4 million to 500,000 cells, respectively. As expected, the percentage of transduced cells 
decreased as cell number increased due to the decreasing MOI (Figure 4.9a). However, 
calculating the utilization efficiencies shows that more cells were actually transduced in 
total as cell number increased (Figure 4.9b). This result supports basic analytical models 
of particle diffusion, which show that microfluidics should have a greater fraction of 
particles adsorbed to a surface for the given transduction time compared to 6-wells95. 
Moreover, the increased number of binding sites from greater cell densities allows more of 
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the available LV to transduce more cells. Thus, the highest utilization efficiency was 
observed for increasing cell numbers. Thus, transductions should utilize as high of a cell 




Figure 4.9: Effect of cell surface density on transduction. (a) For both systems, 
transduction decreased as the number of cells plated increased. (b) Analysis of utilization 
efficiency showed that for greater cell numbers, more LV was actually utilized. 
 
 
4.3.4 Comparison of Microfluidics with Spinoculation 
We sought to determine if our microfluidics outperformed other state of the art 
transduction methods. Of the other state of the art methods, spinoculation is more 
commonly used since the only requirement for use is to have a centrifuge. Although 
transduction was doubled compared to a static 6-well transduction, the microfluidics still 
produced the highest percentage of GFP+ cells with a 30% increase over spinoculation and 
a 178% increase over the static 6-well (Figure 4.10). All following experiments are direct 
comparisons with the static 6-well because conditions can more accurately be matched, 
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bearing in mind that spinoculation would produce transduction levels somewhere in 
between the microfluidic and 6-well. With spinoculation, the extra steps proved to be 
cumbersome, and the extended time outside of a CO2 environment were of concern since 
the media color was bright pink upon removal from the centrifuge.  
 
 
Figure 4.10: Microfluidic comparison to spinoculation. The microfluidic transductions 
were significantly higher than both achieved from spinoculation and the static 6-well. 
 
4.3.5 Microfluidic Transduction Sensitivity to LV Half-life Fluctuations 
Another factor that can affect transduction efficiency is the LV half-life, 
specifically the half-life sensitivity to temperature changes. We sought to determine if 
microfluidics would be less susceptible to LV temperature-based decay. All LV samples 
were used to transduce cells in either a microfluidic or 96-well for 5 hours using the same 
amount of LV (Figure 4.11). Compared to room temperature controls, negligible 
differences in LV samples that had been incubated at 37°C prior to transduction were 
observed for the first 5 hours of incubation. However, after 12 and 24 hours of pre-
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incubation at 37°C, transduction was drastically reduced by as much as 70%. Furthermore, 
the reduction in microfluidic transductions between room temperature and 37°C pre-
incubated LV at 12 and 24 hours were significantly lower than in 96-wells (*p<0.05, 
***p<0.001). These results indicated that although temperature-dependent LV decay 
affected both systems, the microfluidics were still able to more efficiently utilize the 
remaining available LV as seen by the smaller decreases compared to room temperature 
controls for the longer pre-incubation times. This highlights the benefit of minimizing 




Figure 4.11: LV temperature-based decay in microfluidics vs. 6-wells. Comparison of LV 
pre-incubation at room temperature and 37°C prior to transduction demonstrates that 
negligible LV decay occurs within the first 5 hours. However, LV begins to significantly 
decay between 12-24 hours. Microfluidics demonstrate greater resistance to temperature-
related vector degradation. 
 
 
Microfluidic transductions were also consistently several fold higher than 96-well 
controls, though pre-incubation of LV for any amount of time resulted in decreased fold 




despite overall lower fold changes in transduction, LV that had been pre-incubated at 37°C 




Figure 4.12: Comparison of the microfluidic fold change over 96-wells for various LV 
pre-incubation times. As pre-incubation time increases, the fold increases between 
microfluidics and 96-wells decreases, indicating that LV degradation has reduced the 
infectivity or amount of available LV for transduction. 
 
4.3.6 Transduction Kinetics in Microfluidics 
The amount of LV or LV v/v% concentration were previously shown to be 
important parameters for increasing transduction17. However, transduction time is also a 
significant factor when considering the time required for LV particles to diffuse to cells 
and the half-life of the vector96. As expected, increasing the amount of LV used, and 
therefore the LV v/v%, resulted in increased transduction. Gene transfer also increased 
proportionally with transduction time (Figure 4.13a). A basic COMSOL model of LV 




LV had to be increased by threefold to match the experimental conditions, indicating that 
the titer may have been underestimated due to the diffusion-limited titration (Figure 





Figure 4.13: Assessment of transduction kinetics between a 6-well plate and our 
microfluidic system for various MOI. (a) Experimental data with MOI ranging from 0.21-
1.28 (b) Basic COMSOL simulation of transductions in both systems demonstrating that 
the observed trends are due to physics-based differences facilitated by microfluidics. In 
silico concentration had to be increased to match experimental data, indicating that reported 
titers may be underestimates.  
 
 
Furthermore, calculating the utilization efficiency for each condition demonstrated 
that the microfluidics were proportionally more efficient with time, though inversely 
proportionally with the amount of LV used (Figure 4.14). The high utilization efficiencies 
corroborate the underestimated titers, and indicate that the titer may be as much as 5-fold 
higher than originally measured. Interestingly, the utilization efficiency of transductions in 






Figure 4.14: Utilization efficiency has much higher potential with microfluidics 
(µFluidics). The shorter diffusion lengths allow more of the available LV to reach the cells 
with increasing time. Lower MOI produces the greatest differences in utilization efficiency 
because the microfluidics are not diffusion-limited, and nearly all of the LV is used. The 
utilization efficiencies greater than 100% highlight the inaccurate titer, which may actually 
be 2-5 fold higher. 
 
 
Finally, secondary transductions at MOI 0.43 between the microfluidics and 6-
wells confirmed that the microfluidics were indeed more efficient in utilizing the available 
LV (Figure 4.15). An inverse relationship was observed between the primary transduction 
time and the percentage of GFP+ cells from the secondary transduction using the residual 
LV. The secondary microfluidic transductions are consistently lower than the 
complementary secondary 6-well transductions, indicating that there was less LV left over 
from the microfluidic primary transductions. Thus, microfluidics utilized LV more 
efficiently compared to comparable well plates. In the current study, the secondary 
transductions served as a qualitative assessment of leftover vector. However, more accurate 
quantitation may potentially be obtained from performing concurrent titrations in which 
decreasing amounts of LV are used up to the maximum amount of LV originally used in 
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the primary transduction. In addition, the secondary transductions would need to be 
performed for longer periods of time so that the maximum amount of vector can reach the 
cells, though this would be an underestimate due to the short LV half-life and diffusion 
limitations of the 6-well. Alternatively, ultracentrifugation may potentially be used to re-
concentrate the residual vector collected from the microfluidics and 6-wells to transduce 
new cells in microfluidics to eliminate the issues associated with diluting the LV out 
further, though further ultracentrifugation may result in reduced titer or infectivity from 




Figure 4.15: Microfluidics are able to more efficiently utilize available LV. Representative 
experiment of kinetic analysis of transduction and secondary transductions to assess 
leftover LV. Solid bars represent transductions carried out in either the µFluidic (blue) or 
6-well (red). Striped bars represent transductions in which the leftover viral supernatant 
collected at each time point from the primary transductions were used to transduce fresh 
cells in 6-wells after re-suspending to 2 mL total volume for 6 hours. 
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4.3.7 MOI and Utilization Efficiency Are Inversely Proportional 
For constant channel dimensions, increasing the MOI rapidly increased the LV 
v/v% concentration, which lead to nutrient deprivation and vector stock-mediated toxicity 
(Figure 4.16).  
 
Figure 4.16: Comparison of microfluidic and 6-well transductions for increasing MOI. 
*p<0.05, ***p<0.001 two-tailed t-tests comparing microfluidics and 6-wells for each MOI. 
 
As a result, microfluidic transductions initially increased proportionally with MOI, 
though transduction began to decrease past 50% LV v/v% concentration (Figure 4.17). 
This parabolic shape was not observed for 6-well transductions, in which transduction 
consistently increased proportionally with MOI. Even at MOI 4, the 6-well LV v/v% 
concentration was still only 9% versus 97.7% in the microfluidic. Thus, a consistent 
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decrease in fold change between the microfluidic and 6-well transductions were observed 




Figure 4.17: Fold change of microfluidic transductions over 6-wells (n = 3) at various 
MOI. Data represent mean + s.d. of biological replicates from two experiments. Toxicity 
at high LV (v/v)% due to geometric constraints diminishes microfluidic transduction 
efficiency. 
 
Assessing the utilization efficiency between the two systems showed that 
microfluidic transductions are several fold more efficient than 6-wells at low MOI (Figure 
4.18). However, as the amount of vector was increased, the microfluidic utilization 
efficiency rapidly approached that of the 6-well, which steadily decreased at a much slower 
rate as MOI increased. These data highlight the diminishing returns of simply increasing 
the amount of LV used to achieve higher transduction. The microfluidics are able to make 
the most out of smaller amounts of LV, though toxicity from higher vector concentration 
quickly reduces the benefits.  
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Figure 4.18: Utilization efficiency of microfluidic versus 6-well transductions at various 
MOI. 
 
4.3.8 Consecutive Transductions Overcome Geometric Constraints of Microfluidics 
To overcome the geometric constraints of microfluidic transduction that resulted in 
toxicity at high MOI as in Figure 4.16, we investigated the use of consecutive 
transductions to deliver multiple doses of vector at a lower LV v/v% concentration (Figure 
4.19). (1x) transductions equated to MOI 4. Previous studies transducing adherent cells 
with adenovirus in a microfluidic showed that continuous perfusion resulted in 
heterogeneity in cell transduction that was biased toward the inlet where the initial 
concentration was higher97. This also assures that transduction is homogeneous along the 
width of the channel instead of being skewed along the velocity flow profile. Furthermore, 
with continuous perfusion, convection can provide a greater mass flux of vector, but viral 
particles will still have to diffuse between streamlines to reach the cells immobilized to the 
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bottom surface. Therefore, we decided to use consecutive transductions where virus would 
be allowed to diffuse under static conditions toward cells for short periods of time followed 
by re-filling steps to load more vector.  
Under consecutive transduction conditions, cells in the microfluidic were exposed 
to two doses of vector at MOI 1.2, equating to a total (0.6x) MOI 2.4 transduction. Despite 
a 40% reduction in total vector usage, comparable levels of transduction were achieved, 
and the toxicity observed in the microfluidic with high concentration was rescued. 
Assessing the utilization efficiency of the three conditions also showed that the consecutive 
transductions were the most efficient method for higher MOI (Figure 4.19b). Consecutive 
transductions were conducted at (0.6x) instead of (1x) conditions due to the duration of 
transduction. From the kinetic experiments shown in Figure 4.13, it was determined that 
5 hours was sufficient to achieve over 50% of the transduction obtained from a 24-hour 
transduction for each MOI in the microfluidics. Thus, we utilized two 4-hour transductions 
to achieve the same 8-hour transduction time as the static conditions to minimize wasted 
vector. Due to the constraints of a 30% LV (v/v)% concentration to maintain a low dose, 




Figure 4.19: High LV (v/v)% leading to toxicity for high MOI can be rescued using low 
dose consecutive transductions. (a) (1x) MOI 4 microfluidic (µFluidic) transduction at 
97.7% LV (v/v)% results in reduced transduction, but can be restored by using less LV at 
less toxic 30% LV (v/v)% for two 4-hour consecutive transductions, amounting to (0.6x) 
µFluidic transduction (n = 6 (1x) static µFluidic and 6-Well, n = 5 (0.6x) µFluidic). 
*P<0.05, ***P<0.001, One-Way ANOVA. Data represent mean + s.d. of biological 
replicates from four separate experiments ((1x) static conditions) and mean + s.d. of 
technical replicates of one experiment ((0.6x) periodic filling microfluidic).  (b) Virus 
savings and more efficient utilization can be achieved by consecutive transduction contrary 
to simply increasing MOI when high levels of transduction are desired. 
 
4.4  Conclusions 
We conducted an extensive sweep of various parameters that could contribute to 
transduction enhancement in the microfluidic to optimize conditions. Based on our results, 
we determined that minimizing the fluid height was a critical parameter. Previous vector 
titration protocols call for incubating cells in a total volume that is as small as possible.  
Due to surface tension and evaporation issues, there is a physical limit to the obtainable 
minimum height for conventional transduction systems (Figure 4.20). Thus, microfluidics 
may be perfect candidates for next generation transduction platforms. 
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Figure 4.20: Schematic of surface-tension and evaporation limitations on minimum fluid 
height in standard systems. 
 
Seeding cells at the highest density and using the minimum amounts of LV instead 
of pumping in more LV produced the most effective use of available vector. The saturating 
amounts of LV observed in some of the microfluidic transductions indicated that there was 
some sort of biological limitation rather than a diffusion limitation since increased 
concentration did not improve transduction proportionally. These factors are critical 
considerations for future device designs.  
While the microliter-scale working volumes of microfluidic transductions confer 
benefit to transduction efficiency, it can also become a constraint depending on factors 
such as vector titer, nutrient requirements, and increased LV requirements depending on 
cell permissivity to infection. Static microfluidic transductions may physically be unable 
to accommodate the amount of LV particles required to infect all cells in the channel 
without toxicity resulting from high concentrations of viral stock formulation media. To 
address this limitation, we explored the possibility of periodically filling channels laden 
with RetroNectin-immobilized cells at safe LV v/v% concentrations. Previous studies have 
shown that transduction of adherent cell types using adenoviral and retroviral vectors can 
be enhanced with various perfusion regimes. LV can be diluted to safe levels and perfused 
to mitigate the toxicity of higher MOI in flow microfluidic transductions as well, though 
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this may require microfluidics that are specially designed for this specific mode of 
operation. One of the current strategies for large-scale transductions in cell culture bags 
uses RetroNectin coatings to adsorb vector onto the inner surfaces before loading cells and 
then simply flipping after some time to expose cells to fresh virus55. This method basically 
relies on multiple rounds of transduction in principle since cells are exposed to vector from 
one side of the bag and then flipped for exposure to more virus on the other side. Some 
mixing of unbound vector with cells may occur during the process of flipping, which may 
serve to enhance transduction. The microfluidic permits all of these mechanisms to be 
incorporated into a modified transduction protocol by enabling cells to be immobilized in 
the channel and then similarly performing multiple rounds of transduction. Furthermore, 
convective mixing can be more tightly controlled with perfusion and specific channel 
designs such as herringbone structures98. 
Constraints imposed by the target cell type and LV preparation or availability may 
make either time or virus savings more critical. Further considerations of the geometric 
constraints will then need to be considered to determine if a static or flow transduction is 
more appropriate (Figure 4.21). Microfluidics therefore serve as a flexible platform that 
can combine several transduction technologies to maximize efficiency.  
 
Figure 4.21: Illustration of the balance between time and virus savings afforded by the 
microfluidic and factors that determine the mode of usage.  
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CHAPTER 5: ASSESSING MICROFLUIDIC TRANSDUCTION 
EFFICACY IN PRIMARY HUMAN T CELLS 
5.1  Introduction 
Although cell lines provide essential insight necessary to characterize microfluidic 
lentiviral transductions, they present an ideal case for transduction efficiency due to their 
increased permissivity to infection99. Transduction of primary cells pose a much more 
challenging problem due to biological differences and heterogeneity of primary cell 
populations. For instance, LVs are commonly pseudotyped with the vesicular stomatitis 
virus glycoprotein (VSV-G) due to its broad tropism, allowing infection to a broad range 
of cell types47. Recent studies have identified the low-density lipoprotein receptor (LDL-
R) as the receptor to VSV-G, which is expressed differentially in T cells depending on their 
activation state71, 100. Stimulation with interleukin-2 (IL-2) is therefore necessary to activate 
T cells and increase LDL-R expression levels, enabling detectable levels of transduction. 
T cells are becoming a major target for gene therapy due to increasing use of CAR T cells 
in cancer immunotherapy22. The issues of inefficient mass transport of existing systems 
combined with such biological barriers highlight the wastes generated in current clinical 
protocols.  
5.2  Materials and Methods 
5.2.1 Microfluidic Device Fabrication 
CNC micro-milling as described in Section 3.2.2 was used to produce a mold for 
microfluidic devices to assess T cell lentiviral transduction kinetics. The channel height 
from these molds was 210µm, resulting in microfluidics with 200µL volumes. The height 
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was increased in the devices used for these experiments due to the lower titer of the GFP-
LV. At 30% v/v% concentration, the MOI was still only 2.67. The 92µL microfluidics 
made from SU-8 molds were used for the fVIII-LV T cell transductions due to the much 
higher titers. All devices were coated with RetroNectin at a surface concentration of 
2.1µg/cm2.  
5.2.2 T Cell Conditioning and Activation 
Frozen human pan T cells were purchased from AllCells (AllCells, LLC., Alameda, 
CA, USA). Cells were thawed following the AllCells thawing protocol and allowed to 
recover in RPMI 1640 media supplemented with 10% FBS, L-Glutamine, 25 mM HEPES, 
and 1% Pen/Strep for 24 hours. CD3 and CD28-coated beads (Miltenyi Biotec Inc., San 
Diego, CA, USA) were then added to the cells at a 1:1 bead:cell ratio with 100 IU/mL 
human IL-2 (PeproTech, Rocky Hill, NJ, USA) for T cell activation. The cells and beads 
were then transferred to a 6-well plate at a density of 1-2x106 cells/mL/cm2. Cells were 
ready for transduction after a 24-hour activation period. 
5.2.3 T Cell Transduction 
The same stock of GFP-LV from previous cell line transductions discussed in 
Chapter 4 were used for the T cell transduction kinetics experiments. The fVIII LV used 
to quantify T cell transduction efficiency was supplied by Expression Therapeutics, LLC 
(Tucker, GA, USA) and was prepared by commercial manufacturing organizations for 
clinical development of a CD34+ fVIII-LV gene therapy product candidate. The fVIII-LV 
used a CD68 promoter, which is expressed in cells of the myeloid lineage such as 
granulocytes and monocytes. As such, T cells did not actually express fVIII, so VCN 
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analysis was used as the primary readout for transduction efficiency. A reduced dose of 
polybrene at 6µg/mL was used for all T cell transductions to avoid polybrene-associated 
toxicity.  
5.2.4 T Cell Assessment of Transduction Efficiency 
Cells that were transduced with the GFP-LV were stained with eFluor 780 viability 
dye (eBioscience, Inc., San Diego, CA, USA) at least 72 hours post-transduction. T cell 
purity was confirmed with a CD3-V450 (500A2) antibody (BD Biosciences, San Jose, CA, 
USA). Transduction efficiencies were determined as the percentage of GFP+ live cells as 
obtained with a BD LSR II flow cytometer. Cell samples were blinded to the operator 
before processing for vector copy number. Genomic DNA was harvested from cells using 
the DNEasy blood and tissue kit (Qiagen, Valencia, CA, USA). Real-time quantitative PCR 
was used to determine vector copy number. fVIII-transduced cells received identical 
processing, without GFP assessment. An overview of the T cell conditioning from thawing 
to transduction assessment is summarized in Figure 5.1. 
 
 
Figure 5.1: Conditioning of primary human T cells and LV transduction timeline. 
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5.3  Results and Discussion 
5.3.1 Microfluidics Reduce LV Requirements in Primary Human T Cells 
Transduction of primary human T cells has proven to be challenging due to 
biological barriers that are still not fully understood or characterized. We sought to 
determine if microfluidics could improve transduction by overcoming diffusion 
limitations, or if the notoriously low transduction was attributed mostly to biological 
barriers. We first assessed a variety of transduction times to determine the optimum time 
for T cells.  As shown by eFluor 760 dead cell staining, cells were not negatively impacted 
for transduction times shorter than 12 hours, but cell death increased for 24-hour 
transductions (Figure 5.2). Specifically, cell death was significantly greater for the higher 
MOI (5x) 6-well condition, which indicates that cell death may be related to total amount 
of vector since the microfluidics were at the same vector concentration. 
 
Figure 5.2: Percentages of dead T cells for each transduction time. Dead cells were 
quantified by flow cytometry using eFluor 780 staining. 
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GFP expression of cells transduced for 4 and 12 hours in either the microfluidic 
(1x), 6-well (1x), or concentrated 6-well (5x) demonstrated that the kinetics were increased 
between the microfluidic and 6-well using the same amount of LV (Figure 5.3a). Although 
the transduction was similar between the two conditions for 4-hour transductions, a nearly 
20% increase in transduction was observed for 12-hour transductions. The concentrated 6-
well (5x) initially yielded the greatest transduction for 4-hour transductions, but within 12 
hours, the microfluidic was able to obtain the same level of transduction using 5-fold less 
LV. Vector copy number analysis confirmed that transgene integration correlated with GFP 
expression (Figure 5.3b). 
        
 
 
Figure 5.3: Transduction assessment of primary human T cells for 4 and 12 hour 
transductions. (a) Percentages of GFP+ cells assessed by flow cytometry following 
transductions with a GFP-LV in microfluidics or 6-wells for either 4 or 12 hours. (b) 
Average vector copy number of transduced cells. (1x) transductions are MOI 2.67. 
  
 
 To better estimate the utilization efficiency of LV for our primary cell experiments, 
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 Since the VCN represents the average number of vector copies per cell, the 
estimated total number of integrated vector copies can be calculated by multiplying the 
VCN by the number of cells initially transduced. Likewise, the number of viral particles 
used for transduction can be calculated by multiplying the MOI by the number of cells 
initially transduced. Therefore, the VCN utilization efficiency reduces to the ratio of the 
VCN and the MOI. Similar to the trends observed from the cell line transductions, the T 
cell utilization efficiency was highest for microfluidic transductions, and increased at a 




Figure 5.4:  VCN utilization efficiency for various transduction conditions for 4 and 12-
hour transductions (n = 3). Data represent mean + s.d. of technical replicates from one 




5.3.2 Microfluidics Efficiently Transduce Primary T Cells Using FVIII-LV 
With a slightly more optimized parameter space, we transduced primary human T 
cells with a preclinical CD34+ fVIII-LV gene therapy product candidate that was developed 
by the Spencer/Doering laboratories. We tested our microfluidics with this LV for greater 
clinical relevance and its higher titer, which enabled greater MOI to be tested. Although 
fVIII was not produced due to the use of a CD68 myeloid-specific promoter, we obtained 
VCN as a readout for successful transduction. The (1x) microfluidics using MOI 20 
resulted in the highest VCN compared to (1x) 6-wells that used the same amount of fVIII-
LV (Figure 5.5a). Interestingly, the (0.25x) microfluidic conditions achieved the same 
amount of transduction compared to the (1x) 6-wells, indicating that a 4-fold reduction in 
LV usage may be possible using microfluidics. Calculation of the VCN utilization 
efficiency also shows that microfluidic transductions have the highest potential for efficient 
utilization of LV (Figure 5.5b).  
 
Figure 5.5: FVIII-LV transduction of primary human T cells (n = 5). (1x) transduction is 
MOI 20. Data represent mean + s.d. of technical replicates from one experiment. (a) Higher 
vector integration was achieved in the microfluidic (µFluidic) compared to a 6-well using 
the same amount of LV. However, using 75% less LV in a microfluidic resulted in 
comparable levels of gene transfer in the 6-well. (b) LV is more efficiently utilized for 
lower MOI transductions. **P<0.01, ***P<0.001, One-Way ANOVA. 
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5.4  Conclusions 
Through these studies, we developed a better understanding of the capabilities and 
limitations of the microfluidic lentiviral transduction platform in regards to primary human 
cells. Although T cells are a notoriously difficult to transduce cell target, it was 
encouraging to see that improvements could still be realized compared to the current 
standard. Unlike the cell lines, transduction is limited by more than just diffusion 
limitations. Cellular barriers such as insufficient stimulation and restriction factors that 
resist infection significantly decrease the utilization efficiency of microfluidics. The 
methods in which activation and stimulation of cells played a large role in T cell 
susceptibility to transduction, and still requires much optimization. Although further 
evaluation is required, we demonstrated that T cells could successfully be transduced with 
relatively high efficiency using multiple LVs.   
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CHAPTER 6: ASSESSING MICROFLUIDIC TRANSDUCTION 
EFFICACY IN AN EX VIVO MURINE HEMOPHILIA A MODEL 
6.1  Introduction 
Hematopoietic stem cell-based gene therapy offers incredible potential to cure 
hematologic disorders such as hemophilia or sickle cell disease. Since these diseases have 
a genetic basis that results in altered or disrupted production of critical proteins, gene 
therapy can improve or even fully correct these disorders by targeting hematopoietic stem 
cells to re-populate the body with blood cells containing the corrected gene. In patients that 
cannot find a suitable bone marrow donor for allogenic bone marrow transplant, gene 
therapy offers an alternative method that utilizes a patient’s own cells. For this type of 
therapy, it is not only important to achieve efficient genetic modification, but the stem cell 
properties must be preserved so that the cells can continue to self-renew13. We tested the 
microfluidic transduction device for safety and efficacy in a preclinical simulation of 
hemophilia A ex vivo hematopoietic stem cell gene therapy. 
 
6.2  Materials and Methods 
6.2.1 Animal Studies 
All animal studies and procedures were performed at Emory University under the 
guidelines set by the Emory University Institutional Animal Care and Use Committee. 
C57BL/6 Exon-16 (E16)-disrupted hemophilia A mice were used in all animal 
experiments. Generation of this murine model for hemophilia A has been described 
previously. For transduction efficiency studies, both male and female mice between 8-10 
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weeks of age were used. No randomization was carried out to determine animal groups. 
Based on statistical power estimates (alpha = 0.05, power = 0.8, sigma = 0.3) assuming 
fVIII expression levels drawn from previous unpublished animal studies, a minimum of 
three mice per group would be needed to determine differences. Total animal numbers (n) 
for each group are given. An initial pilot experiment was conducted in which Sca-1+ cells 
were transduced for 5 hours in microfluidics and compared to optimized 6-well 
transductions that had previously been investigated by the Spencer/Doering labs. The 
optimized protocol called for two doses of LV over a period of 28 hours. Due to the 
extremely high cell volumetric concentration used in the microfluidic, transduction times 
were reduced to 5 hours, which has been shown to be an effective length for microfluidic 
transduction without inducing detrimental effects from nutrient deprivation. Furthermore, 
extended ex vivo culture of stem cells has been shown to affect differentiation and self-
renewal capacity of hematopoietic stem cells, and was therefore minimized for our 
studies101. The microfluidic transductions used either the same amount of LV or half as 
much. This experiment is outlined below in Figure 6.1, and informed the design of our 
second animal experiment, which aimed to compare and minimize vector dosage between 




Figure 6.1: Schematic of pilot mouse experiments comparing microfluidic transductions 





Figure 6.2: Schematic of mouse experiments comparing microfluidic transductions to an 
equivalent standard protocol using a 6-well plate. 
 
6.2.2 Harvest and Culture of Mouse Sca-1+ Cells 
Bone marrow was isolated from cleaned hind leg femurs and tibias of C57BL/6 
E16 hemophilia A mice with the CD45.1 allele. Sca-1+ cells were incubated with biotin 
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anti-Sca-1 antibody followed by anti-biotin microbeads (Miltenyi Biotec, Inc., San Diego, 
CA, USA) and passed through a magnetic separation column for positive section. Isolated 
cells were then cultured overnight at a density of 2x106 cells/mL in StemPro media 
supplemented with stem cell factor (100 ng/mL), murine interleukin-3 (20 ng/mL), human 
interleukin-11 (100 ng/mL), human Flt-3 ligand (100 ng/mL), StemPro nutrient 
supplement (40x), L-glutamine (100x), and penicillin/streptomycin (100x). 
6.2.3 Transduction of Sca-1+ Cells 
On the day of transduction, 2 million cells were loaded into each bare microfluidic 
and 6-well with 8 µg/mL Polybrene as described above with a clinical grade fVIII-LV for 
5 hours. Cells were then collected, washed, and re-suspended in fresh PBS for transplant. 
 
6.2.4 Transplantation of Transduced Sca-1+ Cells 
At least four hours prior to transplantation, a separate cohort of 8- to 10-week-old 
C56BL/6 E16 hemophilia A mice with the CD45.2 allele were given two doses of lethal 
irradiation at 11 Gy Rad four hours apart. After transduction and washing of LV from the 
donor cells, 1,000,000 cells were transplanted into each host mouse via retro-orbital 
injection.  
 
6.2.5 Bi-weekly Assessment of Sca-1+ Cell Transduction and Engraftment 
Mice were bled every two weeks for the first 8 weeks via tail vein microsampling. 
Flow cytometry was run on collected blood cells and stained for CD45.1 and CD45.2 to 
assess engraftment. The following antibody-fluorophore conjugates were used for flow 
cytometry: CD45.2-APC (558702), Gr1-APC-Cy7 (557661), Mac1-APC-Cy7 (557657), 
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CD45.1-PE (553776), CD3e-V450 (560801), and CD45R/B220-PE-Cy7 (552772) (BD 
Biosciences, San Jose, CA, USA). Complete blood counts were also conducted to monitor 
populations of various white blood cells including lymphocytes, monocytes, and 
granulocytes. Plasma was isolated and used to measure fVIII plasma levels via 
commercially available chromogenic substrate assay (Chromogenix Coatest SP FVIII, 
diaPharma, West Chester, OH, USA). 
6.2.6 Quantification of Vector Copies in Blood, Spleen, and Bone Marrow 
After 16 weeks, mice were euthanized, and cells from blood, spleen, and bone 
marrow were harvested for RT-PCR to quantify LV copy number. Vector copy number 
analysis were conducted as previously described in Section 5.2.4. The operator was blinded 
to the cell samples before processing for vector copy number.  
 
6.3  Results and Discussions 
6.3.1 Microfluidics Reduce Transduction Time in Primary Mouse Cells 
Compared to mice transplanted with cells transduced following the standard 6-well 
protocol, mice that were transplanted with microfluidic-transduced cells utilizing the same 
or half the amount of fVIII-LV produced similar levels of plasma fVIII despite a nearly 5-
fold reduction in LV exposure time. Utilizing this amount of vector, ranging from MOI 10-
40 depending on the amount of cells transduced, all microfluidic-transduced cells restored 
the hemophilic mice to normal fVIII levels. Open shapes indicate transduction of 2 million 
cells versus 4 million cells, indicated with closed shapes. The 26.6µL 6-well transductions 
spanning 28 hours are historical data obtained by the Spencer/Doering lab. We compared 
 99
our modified shortened microfluidic transduction protocol to these data as a standard to 
demonstrate that the microfluidic could indeed reduce transduction times due to the greater 
LV availability and increased kinetics, which is beneficial for shortening ex vivo 





Figure 6.3: Plasma fVIII levels of mice transplanted with cells transduced in a microfluidic 
or 6-well. Amount of LV used and transduction times are indicated. Open shapes indicate 




The vector copy number of harvested blood cells showed that vector integration 
was highest in mice that were transduced with the least amount of LV (Figure 6.4a). 
Therefore, the VCN utilization efficiency was also highest (Figure 6.4b). These results 
indicate that biological barriers such as LV binding may have become rate limiting, leading 
to saturation since doubling the amount of LV did not further improve vector integration. 
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Combined with our previous data and basic analytical models of particle diffusion, we 
expected greater VCN due to the increased LV availability. As such, these data served as 
an upper limit of LV usage in our animal experiments since microfluidics using the same 
amounts of LV as the 6-wells did not demonstrate increased utilization efficiency, and only 
served to decrease transduction time. Overall, these data show that microfluidics can 
achieve sufficient gene transfer while reducing both LV usage and significantly reducing 
transduction times.  Raw VCN and final fVIII data for all mice is shown in Table 6.1. 
         
 
 
Figure 6.4: Assessment of vector integration in pilot mouse studies. (a) VCN analysis of 
blood cells harvested from mice in pilot experiment. (b) VCN utilization efficiency of 
harvested blood cells. Amount of LV used and transduction times are indicated. Open 
shapes indicate 2 million cells were transduced while closed shapes indicate that 4 million 












Table 6.1: VCN and final fVIII data for individual mice from pilot study. 
 
Condition VCN-Blood VCN-SP VCN-BM fVIII (U/mL) 
MOI 20, 2x106 cells 1.01 5.69 4.13 0.76 
MOI 20, 2x106 cells 1.39 3.55 3.24 0.78 
Average + SEM 1.20 + 0.13 4.62 + 0.75 3.68 + 0.32 0.77 + 0.01 
MOI 10, 4x106 cells 1.63 3.66 13.59 0.48 
MOI 10, 4x106 cells 0.80 6.64 3.48 1.03 
Average + SEM 1.22 + 0.29 5.15 + 1.05 8.54 + 3.57 0.75 + 0.2 
MOI 40, 2x106 cells 0.93 2.86 0.31 1.14 
MOI 40, 2x106 cells 0.65 3.40 2.70 0.53 
Average + SEM 0.79 + 0.10 3.13 + 0.19 1.50 + 0.85 0.84 + 0.22 
MOI 20, 4x106 cells 0.74 2.80 2.32 0.48 
MOI 20, 4x106 cells 0.65 3.73 3.27 0.61 
Average + SEM 0.70 + 0.03 3.27 + 0.33 2.80 + 0.33 0.54 + 0.05 
Mock TDX, 2x106 cells 0.05 0.03 0.02 0.00 
Mock TDX, 4x106 cells 0.01 0.01 0.03 0.00 
MOI 20x2, 6-Well Ctrl, 2x106 cells 0.72 - - 0.074 
MOI 20x2, 6-Well Ctrl, 2x106 cells 1.837 - - 1.153 
MOI 20x2, 6-Well Ctrl, 2x106 cells 1.037 - - 0.425 
MOI 20x2, 6-Well Ctrl, 2x106 cells 0.257 - - 0.488 
Average + SEM 0.96 + 0.29 - - 0.54 + 0.20 
 
 
6.3.2 Microfluidics Best 6-wells in Direct Comparisons 
Although our pilot experiment demonstrated potential advantages of microfluidic 
transduction in hematopoietic stem cell gene therapy, we sought to determine if direct 
comparisons showed similar trends as the cell line transductions. In this experiment, all 
cells were transduced for the same amount of time. Direct comparisons were made between 
6-well and microfluidic transductions, indicated by (1x), which is MOI 10. A second set of 
microfluidic transductions were conducted at MOI 2.5 (0.25x) to determine if a reduced 
dose of LV in a microfluidic transduction could obtain similar levels of gene transfer as 
the 6-well. Overall, the amounts of LV used in this study were reduced by 2-8 fold to 
determine the minimum quantities of vector required to restore normal levels of fVIII in 
hemophiliac mice. 
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Over time, fVIII levels steadily increased across all conditions, and stabilized after 
8 weeks (Figure 6.5a). The last three time points taken over a span of 8 weeks were 
averaged for each mouse to obtain an average plasma fVIII measurement (Figure 6.5b). 
Despite using half as much LV compared to the experiment described in Section 6.3.1, 
three of five mice produced normal levels of fVIII when transplanted with cells transduced 
in the microfluidics. Decreasing the LV dosage by four-fold still resulted in sufficient gene 
transfer, enabling all mice to produce moderate to mild levels of fVIII when transplanted 
with (0.25x) microfluidic cells.  
 
 
Figure 6.5: Assessment of fVIII production of mice transplanted with cells transduced in 
(0.25x) microfluidics, (1x) microfluidics, or (1x) 6-wells. (1x) transductions are MOI 10. 
(a) Progression of average fVIII production for each mouse group over 16 weeks. (b) 
Averaged plasma fVIII levels of individual mice between weeks 8 and 16. 3 mice from the 
(1x) microfluidic group were restored to normal fVIII levels. 
 
6.3.3 Microfluidics Do Not Affect Mouse Survival or Engraftment 
Cell viability can be difficult to assess following in vitro transductions since any 
cells that were negatively impacted by microfluidic transduction would quickly be selected 
against while viable cells continued to proliferate. Therefore, in vivo assessment of cell 
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engraftment was critical for determining if microfluidics negatively impacted the cells. 
Donor mice were selected for the CD45.1 allele while recipient mice had the CD45.2 allele. 
Due to lethal irradiation of recipient mice prior to transplantation, nearly all CD45.2+ cells 
were eliminated. Therefore, all blood cells originating from the transplanted HSCs would 
be CD45.1+ while poor engraftment would result in an increase in CD45.2+ cells. 
Monitoring of white blood cell counts, particularly granulocyte, monocyte, and 
lymphocyte counts, were important to assess re-establishment of the immune system. 
Furthermore, due to the CD68-specific promoter used in the fVIII-LV, transgene 
expression would be directed toward cells of the myeloid lineage, which include 
granulocytes and monocytes. Flow cytometry showed that engraftment was high in all 
animals, and increased steadily over time, stabilizing after 8 weeks (Figure 6.6a and b). 
Other than a single outlier in each microfluidic group, all mice displayed >90% CD45.1+ 
cells (Figure 6.6c) and <10% CD45.2+ cells (Figure 6.6d). 
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Figure 6.6: Engraftment of transplanted Sca-1+ cells transduced in microfluidics compared 
to 6-wells. (a) Average percentage of CD45.1+ cells over 16 weeks. (b) Average percentage 
of CD45.2+ cells over 16 weeks. (c) Individual mouse CD45.1+ cells at Week 16. (d) 
Individual mouse CD45.2+ cells at Week 16. 
 
 
 All final white blood cell (Figure 6.7a), lymphocyte (Figure 6.7b), granulocyte 
(Figure 6.7c), and monocyte (Figure 6.7d) cell counts at Week 14 were within normal 







Figure 6.7: Mouse complete blood counts. (a) White blood cell, (b) lymphocytes, (c) 
granulocyte, and (d) monocyte counts over 14 weeks. Dashed lines indicate upper and 
lower bounds for normal levels. The lower bound for monocyte counts is 0.  
 
6.3.4 Viral Vector Integration is Greater in Microfluidic Transductions 
VCN utilization efficiency was calculated from the various tissues harvested and 
assessed for copy number (Figure 6.8a). Individual VCN for blood (Figure 6.8b), bone 
marrow (Figure 6.8c), and spleen (Figure 6.8). Comparable VCN utilization efficiency 
was achieved in both (1x) and (0.25x) microfluidics except for bone marrow cells. Though 
only blood VCN utilization efficiency was statistically significant compared to the 6-well 
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transductions (p<0.05), the majority of mice receiving cells transduced in microfluidics 
demonstrated greater utilization efficiency. Despite significantly lower vector dosages and 
transduction times, (1x) microfluidic transductions were significantly higher with the 
exception of bone marrow VCN. Individual VCN and average fVIII values for each mouse 
are given below in Table 6.2. 
 
 
Figure 6.8: Analysis of vector integration in various mouse tissues. (a) VCN utilization 
efficiency of blood, bone marrow, and spleen. (b) Average VCN of harvested blood cells 
from individual mice per group. (c) Average VCN of harvested bone marrow cells from 
individual mice per group. (d) Average VCN of harvested spleen cells from individual 








Table 6.2: VCN and fVIII for individual mice in direct comparisons. 
 
Sample TDX Condition Blood VCN BM VCN Sp VCN 8-week average fVIII 
964N MOI 2.5 fluidics 0.501 0.174 0.338 0.044 
964R MOI 2.5 fluidics 0.495 0.661 0.578 0.129 
964LL MOI 2.5 fluidics 0.220 0.248 0.234 0.194 
964LR MOI 2.5 fluidics 0.424 0.612 0.518 0.168 
971R MOI 10 Well 1.187 0.968 1.077 0.351 
971L MOI 10 Well 0.882 0.650 0.766 0.145 
973N MOI 10 Well 0.393 0.875 0.634 0.229 
973L MOI 10 Well 0.995 1.030 1.012 0.245 
974N MOI 10 fluidics 1.593 2.106 1.849 0.206 
974L MOI 10 fluidics 1.616 1.068 1.342 0.518 
974R MOI 10 fluidics 1.522 0.845 1.183 0.215 
974LL MOI 10 fluidics 1.801 0.836 1.319 0.549 
974LR MOI 10 fluidics 1.789 0.580 1.185 0.868 
HEMA N/A 0.001 N/A N/A N/A 
 
 
6.4  Conclusions 
From these studies, we were able to definitively show that the microfluidic 
transduction platform did not have any negative impacts on cell viability, engraftment, or 
stem cell properties such as proliferation and differentiation. The long-term survival of 
these mice were not compromised as demonstrated by two separate cohorts which survived 
to 16 and 19 weeks post-transplant. All mice transplanted with microfluidic transduced 
cells from the pilot study using a minimized clinical vector dose produced normal levels 
of fVIII. Using even less vector in the direct 6-well comparisons, three of five mice were 
still restored to normal fVIII levels despite using half as much LV. Combined usage with 
RetroNectin or rapamycin may enable even greater levels of transduction to be achieved102. 
Although the transduction times were already significantly shortened compared to clinical 
protocols, assessment of transduction kinetics with these cells would be interesting to 
determine the minimum time required for effective transduction. 
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CHAPTER 7: CONCLUDING REMARKS AND FUTURE 
DIRECTIONS 
 
In the current work, we translated state-of-the-art transduction protocols to a 
microfluidic platform enabling significant reduction in LV requirements by leveraging the 
micron-scale heights of microfluidics to overcome diffusion limitations of current systems. 
Moreover, the high surface area-to-volume ratio of microfluidics efficiently brings LV into 
cell contact before degradation occurs, reducing transduction times while minimizing LV 
waste and total amounts used by enabling large quantities of cells to be exposed to 
sufficient vector concentrations. Transduction efficiency can be further maximized by 
incorporating existing transduction-enhancing methods. Overall, the microfluidic platform 
outperforms current clinical transduction platforms in all aspects studied.  
As shown from our primary cell data, diffusion limitations are not the only barriers 
to overcome in developing a novel microfluidic platform for gene therapy. While our 
system currently enables enhanced transduction simply from adapting existing protocols 
combined with leveraging the increased mass transport afforded by microfluidics, there are 
still many other areas where improvements can be targeted by changing the design or 
incorporating new microfluidic features that may also be used to actively enhance vector-
cell interactions. Based on the insights gained from this work, it may be equally 
advantageous to leverage the microfluidic system to reduce the expensive cytokine 
requirements currently needed to effectively stimulate or activate primary cells for 
transduction. Future work can focus on using our microfluidics for short term cell culture 
or stimulation to build toward an all-in-one system that can be compatible with existing 
apheresis machines.  
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Among potential device improvements and implementations, additional efforts 
need to be put forth in further characterizing primary T cell and hematopoietic stem cell 
microfluidic transduction. One potential route is to assess CAR-LVs targeting CD19 for 
acute lymphoblastic leukemia. Our previous T cell work was only able to assess vector 
integration as a primary output due to limitations in LV availability. However, it should be 
a top priority to transduce T cells with a CAR-LV so that functional assays can be 
conducted for efficacy or safety profiling. With T cells, tumor cell-specific cytotoxicity 
could be measured to quantify the anti-cancer potential of microfluidic-generated CAR T 
cells. Future hematopoietic stem cell work should investigate the efficacy of microfluidics 
in transducing human CD34+ cells, which are an even more difficult target for genetic 
modification. The cells could then be assessed with the human colony forming cell assay 
using methylcellulose-based media to determine if engraftment has been compromised. 
Alternatively, transduced human CD34+ cells could be transplanted into humanized NOD 
SCID mice to assess engraftment potential.  
Finally, continued efforts to scale up are necessary to make a true impact on gene 
therapy globalization and commercialization. While mock-ups of potential mold designs 
have been considered as discussed in Section 3.5, future designs do not have to be limited 
to PDMS-based devices. One potential idea is to take existing cell culture bags and use a 
hot embossing process to pattern channels within the bag so that the geometry can be 
constrained to have high surface area to volume ratio. Another thought would be to use gas 
permeable sheets of similar materials to cell culture bags and use a xurographic process to 
pattern channels and bond two layers together to form a channel in a bag again. This design 
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could eventually intersect with the previously discussed idea of having the device directly 
interface with apheresis machines.  
Based on our current data as well as our experience with preclinical development 
of a CD34+ fVIII-LV gene therapy product candidate, a clinical production run we estimate 
that an order of magnitude reduction in vector costs per patient may be attainable by using 
microfluidics. Since the LV manufacturing process currently induces high toxicity in the 
mammalian cell required for production, it is not possible to perform long-term continuous 
production. The more viable option is to develop methods to enhance efficiency. Any 
improvements in transduction efficiency will only be enhanced if better technologies arise 
for vector production, but improvements in vector production will not necessarily result in 
greater efficiency. As the current strategy in clinical gene therapy is to apply as much vector 
onto cells as possible without inducing detrimental toxicity, incorporating microfluidic 
transduction can significantly reduce the wastes inherent in current processes and 
overcome issues related to the various sources of variability in vector titration and 
inconsistent infectivity between various cell types. With clinical gene therapy rapidly 
advancing with definite evidence of success and licensed products, associated advances in 
vector manufacturing and utilization are going to be essential to routine clinical 
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